SATUAN ACARA PERKULIAHAN (SAP) I

1. MATA KULIAH Mucosal Immunity pada Kanker Kolorektal

2. KODE MATA KULIAH

3. WAKTU PERTEMUAN 50 Menit.

4. PERTEMUAN KE- 1

5. INDIKATOR Mahasiswa mampu memahami latar belakang penulisan

PENCAPAIAN sari pustaka Mucosal Immunity pada Kanker Kolorektal

6. MATERI POKOK Latar belakang penulisan sari pustaka Mucosal Immunity

pada Kanker Kolorektal

7. PENGALAMAN BELAJAR Memahami latar belakang penulisan sari pustaka Mucosal

Immunity pada Kanker Kolorektal

STRATEGI PEMBELAJARAN

TAHAPAN KEGIATAN KEGIATAN MAHASISWA MEDIA DAN ALAT

DOSEN PEMBELAJARAN
(1) (2) (3) (4)
Pembukaan Memberikan Melihat, mendengarkan SAP, silabus dan jadwal
ulasan umum isi penjelasan study guide, text book,
mata kuliah tugas terstruktur, diktat,
slide presentasi

Penyajian Mengulas latar Melihat, mendengarkan Idem

belakang penjelasan, serta mencatat
penulisan sari
pustaka CAT

Penutup Merangkum latar Menyimak, mengajukan Idem

belakang pertanyaan dan pendapat
penulisan sari dalam diskusi dan meyusun
pustaka CAT laporan kegiatan selama
kuliah
Post test Ujian tertulis, lisan, penilaian/evaluasi terhadap proses pembelajaran, dan
unjuk sikap

Referensi Afiati, Bethy S. Hernowo. 2013. Hubungan ekspresi Ki-67 dengan grading
histopatologi liposarkoma. Majalah kedokteran Bandung ; 45(3).
Agnelli G, Verso M, Ageno W. 2008. The MASTER registry on venous
thromboembolism: description of the study cohort. Thromb Res;121:605-610.

Aguilar C, delVillar V. 2007. Combined D-dimer and clinical probability are

useful for exclusion of recurrent deep venous thrombosis. Am J Hematol
82(1):41-4.

Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R,

Quehenberger P, Zielinski C, Pabinger I. 2010. Prediction of venous
thromboembolism in cancer patients. Blood 116(24):5377-82.

Birdwell BG, Raskob GE, Whitsett TL. 1998. The clinical validity of normal
compression ultrasonography in outpatients suspected of having deep venous
thrombosis. Ann Intern Med 128:1-7.

Brotman DJ, Segal JB, Jani JT, Petty BG, Kickler TS. 2003. Limitations of D-
dimer testing in unselected with suspected venous thromboembolism. Am J
Med 114(4):276282.

Bukhtoryarov OV, Samarin DM. 2015. Pathogenesis of cancer: cancer

reparative trap. Journal of Cancer Therapy 6:399-412.

Bystricky B, Reuben JM, Mego M. 2017. Circulating tumor cells and

coagulation: minirevew. J Crit Rev Onc 114:33-42.

Chew HK, Wun T, Harvey D. 2006. Incidence of venous thromboembolism

and its effect on survival among patients with common cancers. Arch Intern
Med 166:458-464.

Choi Y, Do Hoon Lim, Jeong Il Yu , Kyungil Jo , Do-Hyun Nam, Ho Jun Seol.

2015. Prognostic value of Ki-67 labeling index and postoperative
radiotherapy in WHO grade II Meningioma. Am J Clin Oncol 10:134-358.

Cohen AT, Tapson VF, Bergmann JF. 2008. Venous thromboembolism risk
and prophylaxis in the acute hospital care setting (ENDORSE study): a
multinational cross-sectional study. Lancet 371:387-394.

Collier MEW, Mah PM, Xiao Y, Maraveyas A, Ettelaie C. 2013.

Microparticle-associated tissue factor is recycled by endothelial cells resulting
in enhanched surface tissue factor activity. Thromb Journal 110:966-976.

Cui CJ, Wang GJ, Yang S, Huang SK, Qiao R, Cui W. 2018. Tissue factor
bearing MPs and the risk of venous thrombosis in cancer patients: a meta
analysis. Scientific Rep 8:1675
De Azambuja E, Cardoso F, de Castro G, Jr, Colozza M, Mano MS, Durbecq
V, Sotiriou C, Larsimont D, Piccart- Gebhart MJ, Paesmans M. 2007. Ki-67
as prognostic marker in early breast cancer: a meta-analysis of published
studies involving 12.155 patients. Br J Cancer 96:1504-1513.

Elyamany G, Alzahrani AM, Bukhary E. 2014. Cancer-associated thrombosis:

an overview. Clin Med Oncol 8:129-137

Ettelaie C, Mary EW Collier, Sophie Featherby, Naima E. Benelhaj, John

Greenman, and Anthony Maraveyas. 2016. Analysis of the potential of cancer
cell lines to release tissue factor-containing microvesicles: correlation with
tissue factor and PAR2 expression. Thromb Journal 14(2):1-12.

Falanga A, Russo L, Verzeroli C. 2013. Mechanism of thrombosis in cancer.

Thromb Res.;131:S59-62.

Fraser DG, Moody AR, Morgan PS, Martel A, Devidson I. 2002. Diagnosis of
lower-limb deep venous thrombosis: a prospective blinded study of magnetic
resonance direct thrombus imaging. Ann Intern Med 136(2):89-98.

Gaitini D. 2006. Current approaches and controversial issues in the diagnosis

of deep vein thrombosis via duplex Doppler ultrasound. J Clin Ultrasound
34:289-297.

Geddings JE, Mackman N. Tumor-derived tissue factor-positive

microparticles and venous thrombosis in cancer patients. Blood.
2013;122:1873-80.

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ.
2011. Strategies for subtypes dealing with the diversity of breast cancer:
highlights of the St. Gallen International Expert Consensus on the primary
therapy of early breast cancer Ann Oncol 22:1736-1747.

Heit JA, O'Fallon WM, Petterson TM. 2002. Relative impact of risk factors
for deep vein thrombosis and pulmonary embolism: a population-based study.
Arch Intern Med;162:1245-1248.

Hirsh J, Lee AY. 2002. How we diagnose and threat deep vein thrombosis.
Blood 99:3102-10.

Hisada Y, Gedding JE, Ay C, Mackman N. 2015. Venous thrombosis and

cancer: from mouse models to clinical trials. J Thromb Hem 13:1372-82.

Kakkar AK, Levine M, Pinedo HM. 2003. Venous thrombosis in cancer

patients: insights from the FRONTLINE survey. Oncologist 8:381-388.

Kearon C, Ginsberg JS, Douketis J. 2006. An evaluation of D-dimer in the

diagnosis of pulmonary embolism: a randomized trial. Ann Intern
Med;144:812-821.

Khorana AA, Dalal M, Lin J, Connolly GC. 2013. Incidence and predictors of
venous thromboembolism (VTE) among ambulatory high-risk cancer patients
undergoing chemotherapy in the United States. Cancer 119:648-655.

Khorana AA, Pieter W. Kamphuisen, Guy Meyer, Rupert Bauersachs, Mette

S, Janas, Mikala F.Jarner, Agness YY Lee. 2017. Tissue factor as a predictor
of recurrent venous thromboembolism in malignancy: biomarker analyses of
the catch trial. J Am Clin Onc 35(10):1128.

Levi M. 2016. Management of cancer associated disseminated intravascular

coagulation. Thrombo Res 140:66-70.

Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP,
Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine
MN, Liebman HA, Tempero MA, Wong SL, Prestrud AA, Falanga A. 2013.
Cancer and thrombosis: prevention and treatment of VTE in cancer patients. J
Clin Oncol 31(17):2189-2204.

Machowska M, Wachowicz K, Sopel M, Rzepecki R. 2014. Nuclear location

of tumor suppressor protein maspin inhibits proliferation of breast cancer cells
without affecting proliferation of normal epithelial cells. BMC Cancer 14:142-
148.

Martin B, Paesmans M, Mascaux C, Berghmans T, Lothaire P, Meert AP,

Lafitte JJ, Sculier JP. 2004. Ki-67 expression and patients survival in lung
cancer: systematic review of the literature with meta-analysis. Br J Cancer
91:2018-2025.

Navi BB, Anne S Reiner, Hooman Kamel, Costantino Iadecola, Peter M Okin,
Mitchell SV Elkind, Katherine S Panageas, Lisa M DeAngelis. 2017. Risk of
arterial thromboembolism in patient with cancer. J Am Coll Cardiol 70:926-
938.

Oudega R, Hoes AW, Moons KG. 2005. The Wells rule does not adequately
rule out deep venous thrombosis in primary care patients. Ann Intern Med
143(2):100-7.

Pabinger I. Biomarkers and venous thromboembolism. 2009. Arterioscler

Thromb Vasc Biol 29:332-6.
Prandoni P, Piccioli A, Girolami A. 1999. Cancer and venous
thromboembolism: an overview. Haematologica 84:437-445.

Rabinov K, Paulin S. 1992. Roentgen diagnosis of venous thrombosis in the

leg. Arch Surg.;104(2):134-44.

Razak NBA, Jones G, Bhandari M, Berndt MC, Metharom P. 2018. Cancer

associated thrombosis: an overview of mechanism, risk factors, and treatment.
Cancers 10 (380):1-10.

Sallah S, Wan JY, Nguyen NP. 2002. Venous thrombosis in patients with
solid tumors: determination of frequency and characteristics. Thromb Haemost
87:575-579.

Sampson FC, Goodacre SW, Thomas SM, van Beek EJ. 2007. The accuracy
of MRI in diagnosis of suspected deep vein thrombosis: systematic review and
meta-analysis. Eur Radiol 17:175-181.

Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. 2000. Prognosis of cancers
associated with venous thromboembolism. N Engl J Med 343:1846-1850.

Sorbye SW, Thomas K Kilvaer, Andrej Valkov, Tom Donnem, Eivind

Smeland, Khalid Al-Shibli, Roy M. Bremnes, Lill-Tove Busund. 2012.
Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue
sarcomas. PLoS One 7(10):e47068.

Tadbir AA, Pardis S, Ashkavandi ZJ, Najvani AD, Ashraf MJ, Taheri

A, Zadeh MASardari Y. 2012. Expression of Ki67 and CD105 as proliferation
and angiogenesis markers in salivary gland tumors. Asian Pac J Cancer Prev
13(10):5155-9.

Tao Li Lian, Guang Jiang,Qian Chen and Jun Nian Zheng. 2015. Ki67 is a
promising molecular target in the diagnosis of cancer. Review. Meleculer
Medicine Reports 11:1566-1572.

Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto
S. 2007. Microparticle-associated tissue factor activity: a link between cancer
and thrombosis? J Thromb Haemost 5(3):520-7.

Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. 2013. Epidemiology of
cancer-associated venous thrombosis. Blood 122:1712-1723.

Walker AJ, Baldwin DR, Card TR, Powel HA, Hubbard RB, Grainge MJ.
2016. Risk of venous thromboembolism in people with lung cancer: a cohort
study using linked UK healthcare data. B J Cancer 115:115-121.

Well PS, Anderson Dr, Bormanis J. 1997. Value of assessment of pretest

probability of deep vein thrombosis in clinical management. Lancet
350(9094):1795-1798.

Well PS, Anderson DR, Rodger M. 2003. Evaluation of D-dimer in the

diagnosis of suspected deep vein thrombosis. N Engl J Med 349:1227-1235.

Yang CF, Wu Cui, Jia-Lin Yao, Wen-Ying Sun, Xing-Ku Li, Hong-Jie Wu,
Zhao-Yang Hu, Xiao-Ming Zou. 2016. Plasma tissue factor levels and
microparticle-associated tissue factor activity in patients with gastric cancer.
Int J Clin Exp Pathol 9(3):3495-3503.

Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. 2010. Ki67

in breast cancer: prognostic and predictive potential. Lancet Oncol 11(2):174-
183.

Zierler BK. 2004. Ultrasonography and diagnosis of venous

thromboembolism. Circulation 109(12 Suppl 1):19-114.

Dosen: Prof. drh. I Nyoman Mantik Astawa, Ph. D

Tanda Tangan
 SATUAN ACARA PERKULIAHAN (SAP) II

1. MATA KULIAH Imunologi Kanker pada Kanker Kolorektal

2. KODE MATA KULIAH

3. WAKTU PERTEMUAN 50 Menit.

4. PERTEMUAN KE- 2.

5. INDIKATOR Mahasiswa mampu memahami tentang Imunologi Kanker

PENCAPAIAN pada Kanker Kolorektal

6. MATERI POKOK Imunologi Kanker pada Kanker Kolorektal

7. PENGALAMAN BELAJAR Memahami tentang Imunologi Kanker pada Kanker

Kolorektal

STRATEGI PEMBELAJARAN

TAHAPAN KEGIATAN KEGIATAN MAHASISWA MEDIA DAN ALAT

DOSEN PEMBELAJARAN
(1) (2) (3) (4)
Pembukaan Memberikan Melihat, mendengarkan SAP, silabus dan jadwal
ulasan umum isi penjelasan study guide, text book,
mata kuliah tugas terstruktur, diktat,
slide presentasi

Penyajian Mengulas tentang Melihat, mendengarkan Idem

faktor risiko VTE penjelasan, serta mencatat
pada kanker

Penutup Merangkum Menyimak, mengajukan Idem

uraian faktor pertanyaan dan pendapat
risiko VTE pada dalam diskusi dan meyusun
kanker laporan kegiatan selama
kuliah

Post test Ujian tertulis, lisan, penilaian/evaluasi terhadap proses pembelajaran, dan
 unjuk sikap

Referensi
Afiati, Bethy S. Hernowo. 2013. Hubungan ekspresi Ki-67 dengan grading
histopatologi liposarkoma. Majalah kedokteran Bandung ; 45(3).

Agnelli G, Verso M, Ageno W. 2008. The MASTER registry on venous

thromboembolism: description of the study cohort. Thromb Res;121:605-610.

Aguilar C, delVillar V. 2007. Combined D-dimer and clinical probability are

useful for exclusion of recurrent deep venous thrombosis. Am J Hematol
82(1):41-4.

Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R,

Quehenberger P, Zielinski C, Pabinger I. 2010. Prediction of venous
thromboembolism in cancer patients. Blood 116(24):5377-82.

Birdwell BG, Raskob GE, Whitsett TL. 1998. The clinical validity of normal
compression ultrasonography in outpatients suspected of having deep venous
thrombosis. Ann Intern Med 128:1-7.

Brotman DJ, Segal JB, Jani JT, Petty BG, Kickler TS. 2003. Limitations of D-
dimer testing in unselected with suspected venous thromboembolism. Am J
Med 114(4):276282.

Bukhtoryarov OV, Samarin DM. 2015. Pathogenesis of cancer: cancer

reparative trap. Journal of Cancer Therapy 6:399-412.

Bystricky B, Reuben JM, Mego M. 2017. Circulating tumor cells and

coagulation: minirevew. J Crit Rev Onc 114:33-42.

Chew HK, Wun T, Harvey D. 2006. Incidence of venous thromboembolism

and its effect on survival among patients with common cancers. Arch Intern
Med 166:458-464.

Choi Y, Do Hoon Lim, Jeong Il Yu , Kyungil Jo , Do-Hyun Nam, Ho Jun Seol.

2015. Prognostic value of Ki-67 labeling index and postoperative
radiotherapy in WHO grade II Meningioma. Am J Clin Oncol 10:134-358.

Cohen AT, Tapson VF, Bergmann JF. 2008. Venous thromboembolism risk
and prophylaxis in the acute hospital care setting (ENDORSE study): a
multinational cross-sectional study. Lancet 371:387-394.

Collier MEW, Mah PM, Xiao Y, Maraveyas A, Ettelaie C. 2013.

Microparticle-associated tissue factor is recycled by endothelial cells resulting
in enhanched surface tissue factor activity. Thromb Journal 110:966-976.

Cui CJ, Wang GJ, Yang S, Huang SK, Qiao R, Cui W. 2018. Tissue factor
bearing MPs and the risk of venous thrombosis in cancer patients: a meta
analysis. Scientific Rep 8:1675

De Azambuja E, Cardoso F, de Castro G, Jr, Colozza M, Mano MS, Durbecq

V, Sotiriou C, Larsimont D, Piccart- Gebhart MJ, Paesmans M. 2007. Ki-67
as prognostic marker in early breast cancer: a meta-analysis of published
studies involving 12.155 patients. Br J Cancer 96:1504-1513.

Elyamany G, Alzahrani AM, Bukhary E. 2014. Cancer-associated thrombosis:

an overview. Clin Med Oncol 8:129-137

Ettelaie C, Mary EW Collier, Sophie Featherby, Naima E. Benelhaj, John

Greenman, and Anthony Maraveyas. 2016. Analysis of the potential of cancer
cell lines to release tissue factor-containing microvesicles: correlation with
tissue factor and PAR2 expression. Thromb Journal 14(2):1-12.

Falanga A, Russo L, Verzeroli C. 2013. Mechanism of thrombosis in cancer.

Thromb Res.;131:S59-62.

Fraser DG, Moody AR, Morgan PS, Martel A, Devidson I. 2002. Diagnosis of
lower-limb deep venous thrombosis: a prospective blinded study of magnetic
resonance direct thrombus imaging. Ann Intern Med 136(2):89-98.

Gaitini D. 2006. Current approaches and controversial issues in the diagnosis

of deep vein thrombosis via duplex Doppler ultrasound. J Clin Ultrasound
34:289-297.

Geddings JE, Mackman N. Tumor-derived tissue factor-positive

microparticles and venous thrombosis in cancer patients. Blood.
2013;122:1873-80.

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ.
2011. Strategies for subtypes dealing with the diversity of breast cancer:
highlights of the St. Gallen International Expert Consensus on the primary
therapy of early breast cancer Ann Oncol 22:1736-1747.

Heit JA, O'Fallon WM, Petterson TM. 2002. Relative impact of risk factors
for deep vein thrombosis and pulmonary embolism: a population-based study.
Arch Intern Med;162:1245-1248.

Hirsh J, Lee AY. 2002. How we diagnose and threat deep vein thrombosis.
Blood 99:3102-10.

Hisada Y, Gedding JE, Ay C, Mackman N. 2015. Venous thrombosis and

cancer: from mouse models to clinical trials. J Thromb Hem 13:1372-82.

Kakkar AK, Levine M, Pinedo HM. 2003. Venous thrombosis in cancer

patients: insights from the FRONTLINE survey. Oncologist 8:381-388.

Kearon C, Ginsberg JS, Douketis J. 2006. An evaluation of D-dimer in the

diagnosis of pulmonary embolism: a randomized trial. Ann Intern
Med;144:812-821.

Khorana AA, Dalal M, Lin J, Connolly GC. 2013. Incidence and predictors of
venous thromboembolism (VTE) among ambulatory high-risk cancer patients
undergoing chemotherapy in the United States. Cancer 119:648-655.

Khorana AA, Pieter W. Kamphuisen, Guy Meyer, Rupert Bauersachs, Mette

S, Janas, Mikala F.Jarner, Agness YY Lee. 2017. Tissue factor as a predictor
of recurrent venous thromboembolism in malignancy: biomarker analyses of
the catch trial. J Am Clin Onc 35(10):1128.

Levi M. 2016. Management of cancer associated disseminated intravascular

coagulation. Thrombo Res 140:66-70.

Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP,
Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine
MN, Liebman HA, Tempero MA, Wong SL, Prestrud AA, Falanga A. 2013.
Cancer and thrombosis: prevention and treatment of VTE in cancer patients. J
Clin Oncol 31(17):2189-2204.

Machowska M, Wachowicz K, Sopel M, Rzepecki R. 2014. Nuclear location

of tumor suppressor protein maspin inhibits proliferation of breast cancer cells
without affecting proliferation of normal epithelial cells. BMC Cancer 14:142-
148.

Martin B, Paesmans M, Mascaux C, Berghmans T, Lothaire P, Meert AP,

Lafitte JJ, Sculier JP. 2004. Ki-67 expression and patients survival in lung
cancer: systematic review of the literature with meta-analysis. Br J Cancer
91:2018-2025.

Navi BB, Anne S Reiner, Hooman Kamel, Costantino Iadecola, Peter M Okin,
Mitchell SV Elkind, Katherine S Panageas, Lisa M DeAngelis. 2017. Risk of
arterial thromboembolism in patient with cancer. J Am Coll Cardiol 70:926-
938.
Oudega R, Hoes AW, Moons KG. 2005. The Wells rule does not adequately
rule out deep venous thrombosis in primary care patients. Ann Intern Med
143(2):100-7.

Pabinger I. Biomarkers and venous thromboembolism. 2009. Arterioscler

Thromb Vasc Biol 29:332-6.

Prandoni P, Piccioli A, Girolami A. 1999. Cancer and venous

thromboembolism: an overview. Haematologica 84:437-445.

Rabinov K, Paulin S. 1992. Roentgen diagnosis of venous thrombosis in the

leg. Arch Surg.;104(2):134-44.

Razak NBA, Jones G, Bhandari M, Berndt MC, Metharom P. 2018. Cancer

associated thrombosis: an overview of mechanism, risk factors, and treatment.
Cancers 10 (380):1-10.

Sallah S, Wan JY, Nguyen NP. 2002. Venous thrombosis in patients with
solid tumors: determination of frequency and characteristics. Thromb Haemost
87:575-579.

Sampson FC, Goodacre SW, Thomas SM, van Beek EJ. 2007. The accuracy
of MRI in diagnosis of suspected deep vein thrombosis: systematic review and
meta-analysis. Eur Radiol 17:175-181.

Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. 2000. Prognosis of cancers
associated with venous thromboembolism. N Engl J Med 343:1846-1850.

Sorbye SW, Thomas K Kilvaer, Andrej Valkov, Tom Donnem, Eivind

Smeland, Khalid Al-Shibli, Roy M. Bremnes, Lill-Tove Busund. 2012.
Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue
sarcomas. PLoS One 7(10):e47068.

Tadbir AA, Pardis S, Ashkavandi ZJ, Najvani AD, Ashraf MJ, Taheri

A, Zadeh MASardari Y. 2012. Expression of Ki67 and CD105 as proliferation
and angiogenesis markers in salivary gland tumors. Asian Pac J Cancer Prev
13(10):5155-9.

Tao Li Lian, Guang Jiang,Qian Chen and Jun Nian Zheng. 2015. Ki67 is a
promising molecular target in the diagnosis of cancer. Review. Meleculer
Medicine Reports 11:1566-1572.

Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto
S. 2007. Microparticle-associated tissue factor activity: a link between cancer
and thrombosis? J Thromb Haemost 5(3):520-7.

Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. 2013. Epidemiology of
cancer-associated venous thrombosis. Blood 122:1712-1723.

Walker AJ, Baldwin DR, Card TR, Powel HA, Hubbard RB, Grainge MJ.
2016. Risk of venous thromboembolism in people with lung cancer: a cohort
study using linked UK healthcare data. B J Cancer 115:115-121.

Well PS, Anderson Dr, Bormanis J. 1997. Value of assessment of pretest

probability of deep vein thrombosis in clinical management. Lancet
350(9094):1795-1798.

Well PS, Anderson DR, Rodger M. 2003. Evaluation of D-dimer in the

diagnosis of suspected deep vein thrombosis. N Engl J Med 349:1227-1235.

Yang CF, Wu Cui, Jia-Lin Yao, Wen-Ying Sun, Xing-Ku Li, Hong-Jie Wu,
Zhao-Yang Hu, Xiao-Ming Zou. 2016. Plasma tissue factor levels and
microparticle-associated tissue factor activity in patients with gastric cancer.
Int J Clin Exp Pathol 9(3):3495-3503.

Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. 2010. Ki67

in breast cancer: prognostic and predictive potential. Lancet Oncol 11(2):174-
183.

Zierler BK. 2004. Ultrasonography and diagnosis of venous

thromboembolism. Circulation 109(12 Suppl 1):19-114.

Dosen: Prof. drh. I Nyoman Mantik Astawa, Ph. D

Tanda Tangan
 SATUAN ACARA PERKULIAHAN (SAP) III

1. MATA KULIAH CAT

2. KODE MATA KULIAH

3. WAKTU PERTEMUAN 50 Menit.

4. PERTEMUAN KE- 3.

5. INDIKATOR Mahasiswa mampu memahami aspek molekuler CAT

PENCAPAIAN
6. MATERI POKOK Aspek molekuler CAT
7. PENGALAMAN BELAJAR Memahami aspek molekuler CAT

STRATEGI PEMBELAJARAN

TAHAPAN KEGIATAN KEGIATAN MAHASISWA MEDIA DAN ALAT

DOSEN PEMBELAJARAN
(1) (2) (3) (4)
Pembukaan Memberikan Melihat, mendengarkan SAP, silabus dan jadwal
ulasan umum isi penjelasan study guide, text book,
mata kuliah tugas terstruktur, diktat,
slide presentasi

Penyajian Mengulas aspek Melihat, mendengarkan Idem

molekuler CAT penjelasan, serta mencatat
Penutup Merangkum Menyimak, mengajukan Idem
uraian aspek pertanyaan dan pendapat
molekuler CAT dalam diskusi dan meyusun
laporan kegiatan selama
kuliah
Post test Ujian tertulis, lisan, penilaian/evaluasi terhadap proses pembelajaran, dan
unjuk sikap

Referensi
Afiati, Bethy S. Hernowo. 2013. Hubungan ekspresi Ki-67 dengan grading
histopatologi liposarkoma. Majalah kedokteran Bandung ; 45(3).

Agnelli G, Verso M, Ageno W. 2008. The MASTER registry on venous

thromboembolism: description of the study cohort. Thromb Res;121:605-610.

Aguilar C, delVillar V. 2007. Combined D-dimer and clinical probability are

useful for exclusion of recurrent deep venous thrombosis. Am J Hematol
82(1):41-4.

Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R,

Quehenberger P, Zielinski C, Pabinger I. 2010. Prediction of venous
thromboembolism in cancer patients. Blood 116(24):5377-82.

Birdwell BG, Raskob GE, Whitsett TL. 1998. The clinical validity of normal
compression ultrasonography in outpatients suspected of having deep venous
thrombosis. Ann Intern Med 128:1-7.

Brotman DJ, Segal JB, Jani JT, Petty BG, Kickler TS. 2003. Limitations of D-
dimer testing in unselected with suspected venous thromboembolism. Am J
Med 114(4):276282.

Bukhtoryarov OV, Samarin DM. 2015. Pathogenesis of cancer: cancer

reparative trap. Journal of Cancer Therapy 6:399-412.

Bystricky B, Reuben JM, Mego M. 2017. Circulating tumor cells and

coagulation: minirevew. J Crit Rev Onc 114:33-42.

Chew HK, Wun T, Harvey D. 2006. Incidence of venous thromboembolism

and its effect on survival among patients with common cancers. Arch Intern
Med 166:458-464.

Choi Y, Do Hoon Lim, Jeong Il Yu , Kyungil Jo , Do-Hyun Nam, Ho Jun Seol.

2015. Prognostic value of Ki-67 labeling index and postoperative
radiotherapy in WHO grade II Meningioma. Am J Clin Oncol 10:134-358.

Cohen AT, Tapson VF, Bergmann JF. 2008. Venous thromboembolism risk
and prophylaxis in the acute hospital care setting (ENDORSE study): a
multinational cross-sectional study. Lancet 371:387-394.

Collier MEW, Mah PM, Xiao Y, Maraveyas A, Ettelaie C. 2013.

Microparticle-associated tissue factor is recycled by endothelial cells resulting
in enhanched surface tissue factor activity. Thromb Journal 110:966-976.

Cui CJ, Wang GJ, Yang S, Huang SK, Qiao R, Cui W. 2018. Tissue factor
bearing MPs and the risk of venous thrombosis in cancer patients: a meta
analysis. Scientific Rep 8:1675

De Azambuja E, Cardoso F, de Castro G, Jr, Colozza M, Mano MS, Durbecq

V, Sotiriou C, Larsimont D, Piccart- Gebhart MJ, Paesmans M. 2007. Ki-67
as prognostic marker in early breast cancer: a meta-analysis of published
studies involving 12.155 patients. Br J Cancer 96:1504-1513.

Elyamany G, Alzahrani AM, Bukhary E. 2014. Cancer-associated thrombosis:

an overview. Clin Med Oncol 8:129-137

Ettelaie C, Mary EW Collier, Sophie Featherby, Naima E. Benelhaj, John

Greenman, and Anthony Maraveyas. 2016. Analysis of the potential of cancer
cell lines to release tissue factor-containing microvesicles: correlation with
tissue factor and PAR2 expression. Thromb Journal 14(2):1-12.

Falanga A, Russo L, Verzeroli C. 2013. Mechanism of thrombosis in cancer.

Thromb Res.;131:S59-62.

Fraser DG, Moody AR, Morgan PS, Martel A, Devidson I. 2002. Diagnosis of
lower-limb deep venous thrombosis: a prospective blinded study of magnetic
resonance direct thrombus imaging. Ann Intern Med 136(2):89-98.

Gaitini D. 2006. Current approaches and controversial issues in the diagnosis

of deep vein thrombosis via duplex Doppler ultrasound. J Clin Ultrasound
34:289-297.

Geddings JE, Mackman N. Tumor-derived tissue factor-positive

microparticles and venous thrombosis in cancer patients. Blood.
2013;122:1873-80.

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ.
2011. Strategies for subtypes dealing with the diversity of breast cancer:
highlights of the St. Gallen International Expert Consensus on the primary
therapy of early breast cancer Ann Oncol 22:1736-1747.

Heit JA, O'Fallon WM, Petterson TM. 2002. Relative impact of risk factors
for deep vein thrombosis and pulmonary embolism: a population-based study.
Arch Intern Med;162:1245-1248.

Hirsh J, Lee AY. 2002. How we diagnose and threat deep vein thrombosis.
Blood 99:3102-10.

Hisada Y, Gedding JE, Ay C, Mackman N. 2015. Venous thrombosis and

cancer: from mouse models to clinical trials. J Thromb Hem 13:1372-82.

Kakkar AK, Levine M, Pinedo HM. 2003. Venous thrombosis in cancer

patients: insights from the FRONTLINE survey. Oncologist 8:381-388.

Kearon C, Ginsberg JS, Douketis J. 2006. An evaluation of D-dimer in the

diagnosis of pulmonary embolism: a randomized trial. Ann Intern
Med;144:812-821.

Khorana AA, Dalal M, Lin J, Connolly GC. 2013. Incidence and predictors of
venous thromboembolism (VTE) among ambulatory high-risk cancer patients
undergoing chemotherapy in the United States. Cancer 119:648-655.

Khorana AA, Pieter W. Kamphuisen, Guy Meyer, Rupert Bauersachs, Mette

S, Janas, Mikala F.Jarner, Agness YY Lee. 2017. Tissue factor as a predictor
of recurrent venous thromboembolism in malignancy: biomarker analyses of
the catch trial. J Am Clin Onc 35(10):1128.

Levi M. 2016. Management of cancer associated disseminated intravascular

coagulation. Thrombo Res 140:66-70.

Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP,
Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine
MN, Liebman HA, Tempero MA, Wong SL, Prestrud AA, Falanga A. 2013.
Cancer and thrombosis: prevention and treatment of VTE in cancer patients. J
Clin Oncol 31(17):2189-2204.

Machowska M, Wachowicz K, Sopel M, Rzepecki R. 2014. Nuclear location

of tumor suppressor protein maspin inhibits proliferation of breast cancer cells
without affecting proliferation of normal epithelial cells. BMC Cancer 14:142-
148.

Martin B, Paesmans M, Mascaux C, Berghmans T, Lothaire P, Meert AP,

Lafitte JJ, Sculier JP. 2004. Ki-67 expression and patients survival in lung
cancer: systematic review of the literature with meta-analysis. Br J Cancer
91:2018-2025.

Navi BB, Anne S Reiner, Hooman Kamel, Costantino Iadecola, Peter M Okin,
Mitchell SV Elkind, Katherine S Panageas, Lisa M DeAngelis. 2017. Risk of
arterial thromboembolism in patient with cancer. J Am Coll Cardiol 70:926-
938.
Oudega R, Hoes AW, Moons KG. 2005. The Wells rule does not adequately
rule out deep venous thrombosis in primary care patients. Ann Intern Med
143(2):100-7.

Pabinger I. Biomarkers and venous thromboembolism. 2009. Arterioscler

Thromb Vasc Biol 29:332-6.

Prandoni P, Piccioli A, Girolami A. 1999. Cancer and venous

thromboembolism: an overview. Haematologica 84:437-445.

Rabinov K, Paulin S. 1992. Roentgen diagnosis of venous thrombosis in the

leg. Arch Surg.;104(2):134-44.

Razak NBA, Jones G, Bhandari M, Berndt MC, Metharom P. 2018. Cancer

associated thrombosis: an overview of mechanism, risk factors, and treatment.
Cancers 10 (380):1-10.

Sallah S, Wan JY, Nguyen NP. 2002. Venous thrombosis in patients with
solid tumors: determination of frequency and characteristics. Thromb Haemost
87:575-579.

Sampson FC, Goodacre SW, Thomas SM, van Beek EJ. 2007. The accuracy
of MRI in diagnosis of suspected deep vein thrombosis: systematic review and
meta-analysis. Eur Radiol 17:175-181.

Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. 2000. Prognosis of cancers
associated with venous thromboembolism. N Engl J Med 343:1846-1850.

Sorbye SW, Thomas K Kilvaer, Andrej Valkov, Tom Donnem, Eivind

Smeland, Khalid Al-Shibli, Roy M. Bremnes, Lill-Tove Busund. 2012.
Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue
sarcomas. PLoS One 7(10):e47068.

Tadbir AA, Pardis S, Ashkavandi ZJ, Najvani AD, Ashraf MJ, Taheri

A, Zadeh MASardari Y. 2012. Expression of Ki67 and CD105 as proliferation
and angiogenesis markers in salivary gland tumors. Asian Pac J Cancer Prev
13(10):5155-9.

Tao Li Lian, Guang Jiang,Qian Chen and Jun Nian Zheng. 2015. Ki67 is a
promising molecular target in the diagnosis of cancer. Review. Meleculer
Medicine Reports 11:1566-1572.

Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto
S. 2007. Microparticle-associated tissue factor activity: a link between cancer
and thrombosis? J Thromb Haemost 5(3):520-7.

Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. 2013. Epidemiology of
cancer-associated venous thrombosis. Blood 122:1712-1723.

Walker AJ, Baldwin DR, Card TR, Powel HA, Hubbard RB, Grainge MJ.
2016. Risk of venous thromboembolism in people with lung cancer: a cohort
study using linked UK healthcare data. B J Cancer 115:115-121.

Well PS, Anderson Dr, Bormanis J. 1997. Value of assessment of pretest

probability of deep vein thrombosis in clinical management. Lancet
350(9094):1795-1798.

Well PS, Anderson DR, Rodger M. 2003. Evaluation of D-dimer in the

diagnosis of suspected deep vein thrombosis. N Engl J Med 349:1227-1235.

Yang CF, Wu Cui, Jia-Lin Yao, Wen-Ying Sun, Xing-Ku Li, Hong-Jie Wu,
Zhao-Yang Hu, Xiao-Ming Zou. 2016. Plasma tissue factor levels and
microparticle-associated tissue factor activity in patients with gastric cancer.
Int J Clin Exp Pathol 9(3):3495-3503.

Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. 2010. Ki67

in breast cancer: prognostic and predictive potential. Lancet Oncol 11(2):174-
183.

Zierler BK. 2004. Ultrasonography and diagnosis of venous

thromboembolism. Circulation 109(12 Suppl 1):19-114.

Dosen: Prof Dr dr I Made Bakta SpPD-KHOM

Tanda Tangan
 SATUAN ACARA PERKULIAHAN (SAP) IV

1. MATA KULIAH CAT

2. KODE MATA KULIAH

3. WAKTU PERTEMUAN 50 Menit.

4. PERTEMUAN KE- 4.

5. INDIKATOR Mahasiswa mampu memahami tentang peranan tissue

PENCAPAIAN factor micropraticle dalam trombosis.

6. MATERI POKOK Tissue factor micropraticle dalam trombosis.

7. PENGALAMAN BELAJAR Memahami tentang peranan tissue factor micropraticle

dalam trombosis.

STRATEGI PEMBELAJARAN

TAHAPAN KEGIATAN KEGIATAN MAHASISWA MEDIA DAN ALAT

DOSEN PEMBELAJARAN
(1) (2) (3) (4)
Pembukaan Memberikan Melihat, mendengarkan SAP, silabus dan jadwal
ulasan umum isi penjelasan study guide, text book,
mata kuliah tugas terstruktur, diktat,
slide presentasi

Penyajian Mengulas tentang Melihat, mendengarkan Idem

tentang peranan penjelasan, serta mencatat
tissue factor
 micropraticle
dalam trombosis.
Penutup Merangkum Menyimak, mengajukan Idem
uraian tentang pertanyaan dan pendapat
tentang peranan dalam diskusi dan meyusun
tissue factor laporan kegiatan selama
micropraticle kuliah
dalam trombosis.
Post test Ujian tertulis, lisan, penilaian/evaluasi terhadap proses pembelajaran, dan
unjuk sikap

Referensi
Afiati, Bethy S. Hernowo. 2013. Hubungan ekspresi Ki-67 dengan grading
histopatologi liposarkoma. Majalah kedokteran Bandung ; 45(3).

Agnelli G, Verso M, Ageno W. 2008. The MASTER registry on venous

thromboembolism: description of the study cohort. Thromb Res;121:605-610.

Aguilar C, delVillar V. 2007. Combined D-dimer and clinical probability are

useful for exclusion of recurrent deep venous thrombosis. Am J Hematol
82(1):41-4.

Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R,

Quehenberger P, Zielinski C, Pabinger I. 2010. Prediction of venous
thromboembolism in cancer patients. Blood 116(24):5377-82.

Birdwell BG, Raskob GE, Whitsett TL. 1998. The clinical validity of normal
compression ultrasonography in outpatients suspected of having deep venous
thrombosis. Ann Intern Med 128:1-7.

Brotman DJ, Segal JB, Jani JT, Petty BG, Kickler TS. 2003. Limitations of D-
dimer testing in unselected with suspected venous thromboembolism. Am J
Med 114(4):276282.

Bukhtoryarov OV, Samarin DM. 2015. Pathogenesis of cancer: cancer

reparative trap. Journal of Cancer Therapy 6:399-412.

Bystricky B, Reuben JM, Mego M. 2017. Circulating tumor cells and

coagulation: minirevew. J Crit Rev Onc 114:33-42.

Chew HK, Wun T, Harvey D. 2006. Incidence of venous thromboembolism

and its effect on survival among patients with common cancers. Arch Intern
Med 166:458-464.

Choi Y, Do Hoon Lim, Jeong Il Yu , Kyungil Jo , Do-Hyun Nam, Ho Jun Seol.

2015. Prognostic value of Ki-67 labeling index and postoperative
radiotherapy in WHO grade II Meningioma. Am J Clin Oncol 10:134-358.

Cohen AT, Tapson VF, Bergmann JF. 2008. Venous thromboembolism risk
and prophylaxis in the acute hospital care setting (ENDORSE study): a
multinational cross-sectional study. Lancet 371:387-394.

Collier MEW, Mah PM, Xiao Y, Maraveyas A, Ettelaie C. 2013.

Microparticle-associated tissue factor is recycled by endothelial cells resulting
in enhanched surface tissue factor activity. Thromb Journal 110:966-976.

Cui CJ, Wang GJ, Yang S, Huang SK, Qiao R, Cui W. 2018. Tissue factor
bearing MPs and the risk of venous thrombosis in cancer patients: a meta
analysis. Scientific Rep 8:1675

De Azambuja E, Cardoso F, de Castro G, Jr, Colozza M, Mano MS, Durbecq

V, Sotiriou C, Larsimont D, Piccart- Gebhart MJ, Paesmans M. 2007. Ki-67
as prognostic marker in early breast cancer: a meta-analysis of published
studies involving 12.155 patients. Br J Cancer 96:1504-1513.

Elyamany G, Alzahrani AM, Bukhary E. 2014. Cancer-associated thrombosis:

an overview. Clin Med Oncol 8:129-137

Ettelaie C, Mary EW Collier, Sophie Featherby, Naima E. Benelhaj, John

Greenman, and Anthony Maraveyas. 2016. Analysis of the potential of cancer
cell lines to release tissue factor-containing microvesicles: correlation with
tissue factor and PAR2 expression. Thromb Journal 14(2):1-12.

Falanga A, Russo L, Verzeroli C. 2013. Mechanism of thrombosis in cancer.

Thromb Res.;131:S59-62.

Fraser DG, Moody AR, Morgan PS, Martel A, Devidson I. 2002. Diagnosis of
lower-limb deep venous thrombosis: a prospective blinded study of magnetic
resonance direct thrombus imaging. Ann Intern Med 136(2):89-98.

Gaitini D. 2006. Current approaches and controversial issues in the diagnosis

of deep vein thrombosis via duplex Doppler ultrasound. J Clin Ultrasound
34:289-297.

Geddings JE, Mackman N. Tumor-derived tissue factor-positive

microparticles and venous thrombosis in cancer patients. Blood.
2013;122:1873-80.

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ.
2011. Strategies for subtypes dealing with the diversity of breast cancer:
highlights of the St. Gallen International Expert Consensus on the primary
therapy of early breast cancer Ann Oncol 22:1736-1747.

Heit JA, O'Fallon WM, Petterson TM. 2002. Relative impact of risk factors
for deep vein thrombosis and pulmonary embolism: a population-based study.
Arch Intern Med;162:1245-1248.

Hirsh J, Lee AY. 2002. How we diagnose and threat deep vein thrombosis.
Blood 99:3102-10.

Hisada Y, Gedding JE, Ay C, Mackman N. 2015. Venous thrombosis and

cancer: from mouse models to clinical trials. J Thromb Hem 13:1372-82.

Kakkar AK, Levine M, Pinedo HM. 2003. Venous thrombosis in cancer

patients: insights from the FRONTLINE survey. Oncologist 8:381-388.

Kearon C, Ginsberg JS, Douketis J. 2006. An evaluation of D-dimer in the

diagnosis of pulmonary embolism: a randomized trial. Ann Intern
Med;144:812-821.

Khorana AA, Dalal M, Lin J, Connolly GC. 2013. Incidence and predictors of
venous thromboembolism (VTE) among ambulatory high-risk cancer patients
undergoing chemotherapy in the United States. Cancer 119:648-655.

Khorana AA, Pieter W. Kamphuisen, Guy Meyer, Rupert Bauersachs, Mette

S, Janas, Mikala F.Jarner, Agness YY Lee. 2017. Tissue factor as a predictor
of recurrent venous thromboembolism in malignancy: biomarker analyses of
the catch trial. J Am Clin Onc 35(10):1128.

Levi M. 2016. Management of cancer associated disseminated intravascular

coagulation. Thrombo Res 140:66-70.

Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP,
Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine
MN, Liebman HA, Tempero MA, Wong SL, Prestrud AA, Falanga A. 2013.
Cancer and thrombosis: prevention and treatment of VTE in cancer patients. J
Clin Oncol 31(17):2189-2204.

Machowska M, Wachowicz K, Sopel M, Rzepecki R. 2014. Nuclear location

of tumor suppressor protein maspin inhibits proliferation of breast cancer cells
without affecting proliferation of normal epithelial cells. BMC Cancer 14:142-
148.

Martin B, Paesmans M, Mascaux C, Berghmans T, Lothaire P, Meert AP,

Lafitte JJ, Sculier JP. 2004. Ki-67 expression and patients survival in lung
cancer: systematic review of the literature with meta-analysis. Br J Cancer
91:2018-2025.

Navi BB, Anne S Reiner, Hooman Kamel, Costantino Iadecola, Peter M Okin,
Mitchell SV Elkind, Katherine S Panageas, Lisa M DeAngelis. 2017. Risk of
arterial thromboembolism in patient with cancer. J Am Coll Cardiol 70:926-
938.

Oudega R, Hoes AW, Moons KG. 2005. The Wells rule does not adequately
rule out deep venous thrombosis in primary care patients. Ann Intern Med
143(2):100-7.

Pabinger I. Biomarkers and venous thromboembolism. 2009. Arterioscler

Thromb Vasc Biol 29:332-6.

Prandoni P, Piccioli A, Girolami A. 1999. Cancer and venous

thromboembolism: an overview. Haematologica 84:437-445.

Rabinov K, Paulin S. 1992. Roentgen diagnosis of venous thrombosis in the

leg. Arch Surg.;104(2):134-44.

Razak NBA, Jones G, Bhandari M, Berndt MC, Metharom P. 2018. Cancer

associated thrombosis: an overview of mechanism, risk factors, and treatment.
Cancers 10 (380):1-10.

Sallah S, Wan JY, Nguyen NP. 2002. Venous thrombosis in patients with
solid tumors: determination of frequency and characteristics. Thromb Haemost
87:575-579.

Sampson FC, Goodacre SW, Thomas SM, van Beek EJ. 2007. The accuracy
of MRI in diagnosis of suspected deep vein thrombosis: systematic review and
meta-analysis. Eur Radiol 17:175-181.

Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. 2000. Prognosis of cancers
associated with venous thromboembolism. N Engl J Med 343:1846-1850.

Sorbye SW, Thomas K Kilvaer, Andrej Valkov, Tom Donnem, Eivind

Smeland, Khalid Al-Shibli, Roy M. Bremnes, Lill-Tove Busund. 2012.
Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue
sarcomas. PLoS One 7(10):e47068.

Tadbir AA, Pardis S, Ashkavandi ZJ, Najvani AD, Ashraf MJ, Taheri

A, Zadeh MASardari Y. 2012. Expression of Ki67 and CD105 as proliferation
and angiogenesis markers in salivary gland tumors. Asian Pac J Cancer Prev
13(10):5155-9.
Tao Li Lian, Guang Jiang,Qian Chen and Jun Nian Zheng. 2015. Ki67 is a
promising molecular target in the diagnosis of cancer. Review. Meleculer
Medicine Reports 11:1566-1572.

Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto
S. 2007. Microparticle-associated tissue factor activity: a link between cancer
and thrombosis? J Thromb Haemost 5(3):520-7.

Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. 2013. Epidemiology of
cancer-associated venous thrombosis. Blood 122:1712-1723.

Walker AJ, Baldwin DR, Card TR, Powel HA, Hubbard RB, Grainge MJ.
2016. Risk of venous thromboembolism in people with lung cancer: a cohort
study using linked UK healthcare data. B J Cancer 115:115-121.

Well PS, Anderson Dr, Bormanis J. 1997. Value of assessment of pretest

probability of deep vein thrombosis in clinical management. Lancet
350(9094):1795-1798.

Well PS, Anderson DR, Rodger M. 2003. Evaluation of D-dimer in the

diagnosis of suspected deep vein thrombosis. N Engl J Med 349:1227-1235.

Yang CF, Wu Cui, Jia-Lin Yao, Wen-Ying Sun, Xing-Ku Li, Hong-Jie Wu,
Zhao-Yang Hu, Xiao-Ming Zou. 2016. Plasma tissue factor levels and
microparticle-associated tissue factor activity in patients with gastric cancer.
Int J Clin Exp Pathol 9(3):3495-3503.

Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. 2010. Ki67

in breast cancer: prognostic and predictive potential. Lancet Oncol 11(2):174-
183.

Zierler BK. 2004. Ultrasonography and diagnosis of venous

thromboembolism. Circulation 109(12 Suppl 1):19-114.

Dosen: Prof Dr dr I Made Bakta SpPD-KHOM

Tanda Tangan
 SATUAN ACARA PERKULIAHAN (SAP) V

1. MATA KULIAH CAT

2. KODE MATA KULIAH

3. WAKTU PERTEMUAN 50 Menit.

4. PERTEMUAN KE- 5.

5. INDIKATOR Mahasiswa mampu memahami peranan indek proliferasi

PENCAPAIAN kanker dalam trombosis.

6. MATERI POKOK Peranan indek proliferasi kanker dalam trombosis.

7. PENGALAMAN BELAJAR Memahami peranan indek proliferasi kanker dalam

trombosis.

STRATEGI PEMBELAJARAN

TAHAPAN KEGIATAN KEGIATAN MAHASISWA MEDIA DAN ALAT

DOSEN PEMBELAJARAN
(1) (2) (3) (4)
Pembukaan Memberikan Melihat, mendengarkan SAP, silabus dan jadwal
 ulasan umum isi penjelasan study guide, text book,
mata kuliah tugas terstruktur, diktat,
slide presentasi

Penyajian Mengulas tentang Melihat, mendengarkan Idem

peranan indek penjelasan, serta mencatat
proliferasi kanker
dalam trombosis.

Penutup Merangkum Menyimak, mengajukan Idem

uraian tentang pertanyaan dan pendapat
peranan indek dalam diskusi dan meyusun
proliferasi kanker laporan kegiatan selama
dalam trombosis. kuliah

Post test Ujian tertulis, lisan, penilaian/evaluasi terhadap proses pembelajaran, dan
unjuk sikap

Referensi
Afiati, Bethy S. Hernowo. 2013. Hubungan ekspresi Ki-67 dengan grading
histopatologi liposarkoma. Majalah kedokteran Bandung ; 45(3).

Agnelli G, Verso M, Ageno W. 2008. The MASTER registry on venous

thromboembolism: description of the study cohort. Thromb Res;121:605-610.

Aguilar C, delVillar V. 2007. Combined D-dimer and clinical probability are

useful for exclusion of recurrent deep venous thrombosis. Am J Hematol
82(1):41-4.

Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R,

Quehenberger P, Zielinski C, Pabinger I. 2010. Prediction of venous
thromboembolism in cancer patients. Blood 116(24):5377-82.

Birdwell BG, Raskob GE, Whitsett TL. 1998. The clinical validity of normal
compression ultrasonography in outpatients suspected of having deep venous
thrombosis. Ann Intern Med 128:1-7.

Brotman DJ, Segal JB, Jani JT, Petty BG, Kickler TS. 2003. Limitations of D-
dimer testing in unselected with suspected venous thromboembolism. Am J
Med 114(4):276282.

Bukhtoryarov OV, Samarin DM. 2015. Pathogenesis of cancer: cancer

reparative trap. Journal of Cancer Therapy 6:399-412.

Bystricky B, Reuben JM, Mego M. 2017. Circulating tumor cells and

coagulation: minirevew. J Crit Rev Onc 114:33-42.
Chew HK, Wun T, Harvey D. 2006. Incidence of venous thromboembolism
and its effect on survival among patients with common cancers. Arch Intern
Med 166:458-464.

Choi Y, Do Hoon Lim, Jeong Il Yu , Kyungil Jo , Do-Hyun Nam, Ho Jun Seol.

2015. Prognostic value of Ki-67 labeling index and postoperative
radiotherapy in WHO grade II Meningioma. Am J Clin Oncol 10:134-358.

Cohen AT, Tapson VF, Bergmann JF. 2008. Venous thromboembolism risk
and prophylaxis in the acute hospital care setting (ENDORSE study): a
multinational cross-sectional study. Lancet 371:387-394.

Collier MEW, Mah PM, Xiao Y, Maraveyas A, Ettelaie C. 2013.

Microparticle-associated tissue factor is recycled by endothelial cells resulting
in enhanched surface tissue factor activity. Thromb Journal 110:966-976.

Cui CJ, Wang GJ, Yang S, Huang SK, Qiao R, Cui W. 2018. Tissue factor
bearing MPs and the risk of venous thrombosis in cancer patients: a meta
analysis. Scientific Rep 8:1675

De Azambuja E, Cardoso F, de Castro G, Jr, Colozza M, Mano MS, Durbecq

V, Sotiriou C, Larsimont D, Piccart- Gebhart MJ, Paesmans M. 2007. Ki-67
as prognostic marker in early breast cancer: a meta-analysis of published
studies involving 12.155 patients. Br J Cancer 96:1504-1513.

Elyamany G, Alzahrani AM, Bukhary E. 2014. Cancer-associated thrombosis:

an overview. Clin Med Oncol 8:129-137

Ettelaie C, Mary EW Collier, Sophie Featherby, Naima E. Benelhaj, John

Greenman, and Anthony Maraveyas. 2016. Analysis of the potential of cancer
cell lines to release tissue factor-containing microvesicles: correlation with
tissue factor and PAR2 expression. Thromb Journal 14(2):1-12.

Falanga A, Russo L, Verzeroli C. 2013. Mechanism of thrombosis in cancer.

Thromb Res.;131:S59-62.

Fraser DG, Moody AR, Morgan PS, Martel A, Devidson I. 2002. Diagnosis of
lower-limb deep venous thrombosis: a prospective blinded study of magnetic
resonance direct thrombus imaging. Ann Intern Med 136(2):89-98.

Gaitini D. 2006. Current approaches and controversial issues in the diagnosis

of deep vein thrombosis via duplex Doppler ultrasound. J Clin Ultrasound
34:289-297.

Geddings JE, Mackman N. Tumor-derived tissue factor-positive

microparticles and venous thrombosis in cancer patients. Blood.
2013;122:1873-80.

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ.
2011. Strategies for subtypes dealing with the diversity of breast cancer:
highlights of the St. Gallen International Expert Consensus on the primary
therapy of early breast cancer Ann Oncol 22:1736-1747.

Heit JA, O'Fallon WM, Petterson TM. 2002. Relative impact of risk factors
for deep vein thrombosis and pulmonary embolism: a population-based study.
Arch Intern Med;162:1245-1248.

Hirsh J, Lee AY. 2002. How we diagnose and threat deep vein thrombosis.
Blood 99:3102-10.

Hisada Y, Gedding JE, Ay C, Mackman N. 2015. Venous thrombosis and

cancer: from mouse models to clinical trials. J Thromb Hem 13:1372-82.

Kakkar AK, Levine M, Pinedo HM. 2003. Venous thrombosis in cancer

patients: insights from the FRONTLINE survey. Oncologist 8:381-388.

Kearon C, Ginsberg JS, Douketis J. 2006. An evaluation of D-dimer in the

diagnosis of pulmonary embolism: a randomized trial. Ann Intern
Med;144:812-821.

Khorana AA, Dalal M, Lin J, Connolly GC. 2013. Incidence and predictors of
venous thromboembolism (VTE) among ambulatory high-risk cancer patients
undergoing chemotherapy in the United States. Cancer 119:648-655.

Khorana AA, Pieter W. Kamphuisen, Guy Meyer, Rupert Bauersachs, Mette

S, Janas, Mikala F.Jarner, Agness YY Lee. 2017. Tissue factor as a predictor
of recurrent venous thromboembolism in malignancy: biomarker analyses of
the catch trial. J Am Clin Onc 35(10):1128.

Levi M. 2016. Management of cancer associated disseminated intravascular

coagulation. Thrombo Res 140:66-70.

Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP,
Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine
MN, Liebman HA, Tempero MA, Wong SL, Prestrud AA, Falanga A. 2013.
Cancer and thrombosis: prevention and treatment of VTE in cancer patients. J
Clin Oncol 31(17):2189-2204.

Machowska M, Wachowicz K, Sopel M, Rzepecki R. 2014. Nuclear location

of tumor suppressor protein maspin inhibits proliferation of breast cancer cells
without affecting proliferation of normal epithelial cells. BMC Cancer 14:142-
148.

Martin B, Paesmans M, Mascaux C, Berghmans T, Lothaire P, Meert AP,

Lafitte JJ, Sculier JP. 2004. Ki-67 expression and patients survival in lung
cancer: systematic review of the literature with meta-analysis. Br J Cancer
91:2018-2025.

Navi BB, Anne S Reiner, Hooman Kamel, Costantino Iadecola, Peter M Okin,
Mitchell SV Elkind, Katherine S Panageas, Lisa M DeAngelis. 2017. Risk of
arterial thromboembolism in patient with cancer. J Am Coll Cardiol 70:926-
938.

Oudega R, Hoes AW, Moons KG. 2005. The Wells rule does not adequately
rule out deep venous thrombosis in primary care patients. Ann Intern Med
143(2):100-7.

Pabinger I. Biomarkers and venous thromboembolism. 2009. Arterioscler

Thromb Vasc Biol 29:332-6.

Prandoni P, Piccioli A, Girolami A. 1999. Cancer and venous

thromboembolism: an overview. Haematologica 84:437-445.

Rabinov K, Paulin S. 1992. Roentgen diagnosis of venous thrombosis in the

leg. Arch Surg.;104(2):134-44.

Razak NBA, Jones G, Bhandari M, Berndt MC, Metharom P. 2018. Cancer

associated thrombosis: an overview of mechanism, risk factors, and treatment.
Cancers 10 (380):1-10.

Sallah S, Wan JY, Nguyen NP. 2002. Venous thrombosis in patients with
solid tumors: determination of frequency and characteristics. Thromb Haemost
87:575-579.

Sampson FC, Goodacre SW, Thomas SM, van Beek EJ. 2007. The accuracy
of MRI in diagnosis of suspected deep vein thrombosis: systematic review and
meta-analysis. Eur Radiol 17:175-181.

Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. 2000. Prognosis of cancers
associated with venous thromboembolism. N Engl J Med 343:1846-1850.

Sorbye SW, Thomas K Kilvaer, Andrej Valkov, Tom Donnem, Eivind

Smeland, Khalid Al-Shibli, Roy M. Bremnes, Lill-Tove Busund. 2012.
Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue
sarcomas. PLoS One 7(10):e47068.

Tadbir AA, Pardis S, Ashkavandi ZJ, Najvani AD, Ashraf MJ, Taheri

A, Zadeh MASardari Y. 2012. Expression of Ki67 and CD105 as proliferation
and angiogenesis markers in salivary gland tumors. Asian Pac J Cancer Prev
13(10):5155-9.

Tao Li Lian, Guang Jiang,Qian Chen and Jun Nian Zheng. 2015. Ki67 is a
promising molecular target in the diagnosis of cancer. Review. Meleculer
Medicine Reports 11:1566-1572.

Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto
S. 2007. Microparticle-associated tissue factor activity: a link between cancer
and thrombosis? J Thromb Haemost 5(3):520-7.

Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. 2013. Epidemiology of
cancer-associated venous thrombosis. Blood 122:1712-1723.

Walker AJ, Baldwin DR, Card TR, Powel HA, Hubbard RB, Grainge MJ.
2016. Risk of venous thromboembolism in people with lung cancer: a cohort
study using linked UK healthcare data. B J Cancer 115:115-121.

Well PS, Anderson Dr, Bormanis J. 1997. Value of assessment of pretest

probability of deep vein thrombosis in clinical management. Lancet
350(9094):1795-1798.

Well PS, Anderson DR, Rodger M. 2003. Evaluation of D-dimer in the

diagnosis of suspected deep vein thrombosis. N Engl J Med 349:1227-1235.

Yang CF, Wu Cui, Jia-Lin Yao, Wen-Ying Sun, Xing-Ku Li, Hong-Jie Wu,
Zhao-Yang Hu, Xiao-Ming Zou. 2016. Plasma tissue factor levels and
microparticle-associated tissue factor activity in patients with gastric cancer.
Int J Clin Exp Pathol 9(3):3495-3503.

Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. 2010. Ki67

in breast cancer: prognostic and predictive potential. Lancet Oncol 11(2):174-
183.

Zierler BK. 2004. Ultrasonography and diagnosis of venous

thromboembolism. Circulation 109(12 Suppl 1):19-114.

Dosen: Prof Dr dr I Made Bakta SpPD-KHOM

Tanda Tangan
 SATUAN ACARA PERKULIAHAN (SAP) VI

1. MATA KULIAH CAT

2. KODE MATA KULIAH

3. WAKTU PERTEMUAN 50 Menit.

4. PERTEMUAN KE- 6.

5. INDIKATOR Mahasiswa mampu memahami diagnosis VTE pada

PENCAPAIAN pasien kanker
6. MATERI POKOK Diagnosis VTE pada pasien kanker
7. PENGALAMAN BELAJAR Memahami diagnosis VTE pada pasien kanker

STRATEGI PEMBELAJARAN

TAHAPAN KEGIATAN KEGIATAN MAHASISWA MEDIA DAN ALAT

DOSEN PEMBELAJARAN
 (1) (2) (3) (4)
Pembukaan Memberikan Melihat, mendengarkan SAP, silabus dan jadwal
ulasan umum isi penjelasan study guide, text book,
mata kuliah tugas terstruktur, diktat,
slide presentasi

Penyajian Mengulas tentang Melihat, mendengarkan Idem

diagnosis VTE penjelasan, serta mencatat
pada pasien
kanker.

Penutup Merangkum Menyimak, mengajukan Idem

uraian tentang pertanyaan dan pendapat
diagnosis VTE dalam diskusi dan meyusun
pada pasien laporan kegiatan selama
kanker. kuliah

Post test Ujian tertulis, lisan, penilaian/evaluasi terhadap proses pembelajaran, dan
unjuk sikap

Referensi
Afiati, Bethy S. Hernowo. 2013. Hubungan ekspresi Ki-67 dengan grading
histopatologi liposarkoma. Majalah kedokteran Bandung ; 45(3).

Agnelli G, Verso M, Ageno W. 2008. The MASTER registry on venous

thromboembolism: description of the study cohort. Thromb Res;121:605-610.

Aguilar C, delVillar V. 2007. Combined D-dimer and clinical probability are

useful for exclusion of recurrent deep venous thrombosis. Am J Hematol
82(1):41-4.

Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R,

Quehenberger P, Zielinski C, Pabinger I. 2010. Prediction of venous
thromboembolism in cancer patients. Blood 116(24):5377-82.

Birdwell BG, Raskob GE, Whitsett TL. 1998. The clinical validity of normal
compression ultrasonography in outpatients suspected of having deep venous
thrombosis. Ann Intern Med 128:1-7.

Brotman DJ, Segal JB, Jani JT, Petty BG, Kickler TS. 2003. Limitations of D-
dimer testing in unselected with suspected venous thromboembolism. Am J
Med 114(4):276282.

Bukhtoryarov OV, Samarin DM. 2015. Pathogenesis of cancer: cancer

reparative trap. Journal of Cancer Therapy 6:399-412.

Bystricky B, Reuben JM, Mego M. 2017. Circulating tumor cells and

coagulation: minirevew. J Crit Rev Onc 114:33-42.

Chew HK, Wun T, Harvey D. 2006. Incidence of venous thromboembolism

and its effect on survival among patients with common cancers. Arch Intern
Med 166:458-464.

Choi Y, Do Hoon Lim, Jeong Il Yu , Kyungil Jo , Do-Hyun Nam, Ho Jun Seol.

2015. Prognostic value of Ki-67 labeling index and postoperative
radiotherapy in WHO grade II Meningioma. Am J Clin Oncol 10:134-358.

Cohen AT, Tapson VF, Bergmann JF. 2008. Venous thromboembolism risk
and prophylaxis in the acute hospital care setting (ENDORSE study): a
multinational cross-sectional study. Lancet 371:387-394.

Collier MEW, Mah PM, Xiao Y, Maraveyas A, Ettelaie C. 2013.

Microparticle-associated tissue factor is recycled by endothelial cells resulting
in enhanched surface tissue factor activity. Thromb Journal 110:966-976.

Cui CJ, Wang GJ, Yang S, Huang SK, Qiao R, Cui W. 2018. Tissue factor
bearing MPs and the risk of venous thrombosis in cancer patients: a meta
analysis. Scientific Rep 8:1675

De Azambuja E, Cardoso F, de Castro G, Jr, Colozza M, Mano MS, Durbecq

V, Sotiriou C, Larsimont D, Piccart- Gebhart MJ, Paesmans M. 2007. Ki-67
as prognostic marker in early breast cancer: a meta-analysis of published
studies involving 12.155 patients. Br J Cancer 96:1504-1513.

Elyamany G, Alzahrani AM, Bukhary E. 2014. Cancer-associated thrombosis:

an overview. Clin Med Oncol 8:129-137

Ettelaie C, Mary EW Collier, Sophie Featherby, Naima E. Benelhaj, John

Greenman, and Anthony Maraveyas. 2016. Analysis of the potential of cancer
cell lines to release tissue factor-containing microvesicles: correlation with
tissue factor and PAR2 expression. Thromb Journal 14(2):1-12.

Falanga A, Russo L, Verzeroli C. 2013. Mechanism of thrombosis in cancer.

Thromb Res.;131:S59-62.

Fraser DG, Moody AR, Morgan PS, Martel A, Devidson I. 2002. Diagnosis of
lower-limb deep venous thrombosis: a prospective blinded study of magnetic
resonance direct thrombus imaging. Ann Intern Med 136(2):89-98.

Gaitini D. 2006. Current approaches and controversial issues in the diagnosis

of deep vein thrombosis via duplex Doppler ultrasound. J Clin Ultrasound
34:289-297.

Geddings JE, Mackman N. Tumor-derived tissue factor-positive

microparticles and venous thrombosis in cancer patients. Blood.
2013;122:1873-80.

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ.
2011. Strategies for subtypes dealing with the diversity of breast cancer:
highlights of the St. Gallen International Expert Consensus on the primary
therapy of early breast cancer Ann Oncol 22:1736-1747.

Heit JA, O'Fallon WM, Petterson TM. 2002. Relative impact of risk factors
for deep vein thrombosis and pulmonary embolism: a population-based study.
Arch Intern Med;162:1245-1248.

Hirsh J, Lee AY. 2002. How we diagnose and threat deep vein thrombosis.
Blood 99:3102-10.

Hisada Y, Gedding JE, Ay C, Mackman N. 2015. Venous thrombosis and

cancer: from mouse models to clinical trials. J Thromb Hem 13:1372-82.

Kakkar AK, Levine M, Pinedo HM. 2003. Venous thrombosis in cancer

patients: insights from the FRONTLINE survey. Oncologist 8:381-388.

Kearon C, Ginsberg JS, Douketis J. 2006. An evaluation of D-dimer in the

diagnosis of pulmonary embolism: a randomized trial. Ann Intern
Med;144:812-821.

Khorana AA, Dalal M, Lin J, Connolly GC. 2013. Incidence and predictors of
venous thromboembolism (VTE) among ambulatory high-risk cancer patients
undergoing chemotherapy in the United States. Cancer 119:648-655.

Khorana AA, Pieter W. Kamphuisen, Guy Meyer, Rupert Bauersachs, Mette

S, Janas, Mikala F.Jarner, Agness YY Lee. 2017. Tissue factor as a predictor
of recurrent venous thromboembolism in malignancy: biomarker analyses of
the catch trial. J Am Clin Onc 35(10):1128.

Levi M. 2016. Management of cancer associated disseminated intravascular

coagulation. Thrombo Res 140:66-70.

Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP,
Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine
MN, Liebman HA, Tempero MA, Wong SL, Prestrud AA, Falanga A. 2013.
Cancer and thrombosis: prevention and treatment of VTE in cancer patients. J
Clin Oncol 31(17):2189-2204.

Machowska M, Wachowicz K, Sopel M, Rzepecki R. 2014. Nuclear location

of tumor suppressor protein maspin inhibits proliferation of breast cancer cells
without affecting proliferation of normal epithelial cells. BMC Cancer 14:142-
148.

Martin B, Paesmans M, Mascaux C, Berghmans T, Lothaire P, Meert AP,

Lafitte JJ, Sculier JP. 2004. Ki-67 expression and patients survival in lung
cancer: systematic review of the literature with meta-analysis. Br J Cancer
91:2018-2025.

Navi BB, Anne S Reiner, Hooman Kamel, Costantino Iadecola, Peter M Okin,
Mitchell SV Elkind, Katherine S Panageas, Lisa M DeAngelis. 2017. Risk of
arterial thromboembolism in patient with cancer. J Am Coll Cardiol 70:926-
938.

Oudega R, Hoes AW, Moons KG. 2005. The Wells rule does not adequately
rule out deep venous thrombosis in primary care patients. Ann Intern Med
143(2):100-7.

Pabinger I. Biomarkers and venous thromboembolism. 2009. Arterioscler

Thromb Vasc Biol 29:332-6.

Prandoni P, Piccioli A, Girolami A. 1999. Cancer and venous

thromboembolism: an overview. Haematologica 84:437-445.

Rabinov K, Paulin S. 1992. Roentgen diagnosis of venous thrombosis in the

leg. Arch Surg.;104(2):134-44.

Razak NBA, Jones G, Bhandari M, Berndt MC, Metharom P. 2018. Cancer

associated thrombosis: an overview of mechanism, risk factors, and treatment.
Cancers 10 (380):1-10.

Sallah S, Wan JY, Nguyen NP. 2002. Venous thrombosis in patients with
solid tumors: determination of frequency and characteristics. Thromb Haemost
87:575-579.

Sampson FC, Goodacre SW, Thomas SM, van Beek EJ. 2007. The accuracy
of MRI in diagnosis of suspected deep vein thrombosis: systematic review and
meta-analysis. Eur Radiol 17:175-181.

Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. 2000. Prognosis of cancers
associated with venous thromboembolism. N Engl J Med 343:1846-1850.
Sorbye SW, Thomas K Kilvaer, Andrej Valkov, Tom Donnem, Eivind
Smeland, Khalid Al-Shibli, Roy M. Bremnes, Lill-Tove Busund. 2012.
Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue
sarcomas. PLoS One 7(10):e47068.

Tadbir AA, Pardis S, Ashkavandi ZJ, Najvani AD, Ashraf MJ, Taheri

A, Zadeh MASardari Y. 2012. Expression of Ki67 and CD105 as proliferation
and angiogenesis markers in salivary gland tumors. Asian Pac J Cancer Prev
13(10):5155-9.

Tao Li Lian, Guang Jiang,Qian Chen and Jun Nian Zheng. 2015. Ki67 is a
promising molecular target in the diagnosis of cancer. Review. Meleculer
Medicine Reports 11:1566-1572.

Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto
S. 2007. Microparticle-associated tissue factor activity: a link between cancer
and thrombosis? J Thromb Haemost 5(3):520-7.

Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. 2013. Epidemiology of
cancer-associated venous thrombosis. Blood 122:1712-1723.

Walker AJ, Baldwin DR, Card TR, Powel HA, Hubbard RB, Grainge MJ.
2016. Risk of venous thromboembolism in people with lung cancer: a cohort
study using linked UK healthcare data. B J Cancer 115:115-121.

Well PS, Anderson Dr, Bormanis J. 1997. Value of assessment of pretest

probability of deep vein thrombosis in clinical management. Lancet
350(9094):1795-1798.

Well PS, Anderson DR, Rodger M. 2003. Evaluation of D-dimer in the

diagnosis of suspected deep vein thrombosis. N Engl J Med 349:1227-1235.

Yang CF, Wu Cui, Jia-Lin Yao, Wen-Ying Sun, Xing-Ku Li, Hong-Jie Wu,
Zhao-Yang Hu, Xiao-Ming Zou. 2016. Plasma tissue factor levels and
microparticle-associated tissue factor activity in patients with gastric cancer.
Int J Clin Exp Pathol 9(3):3495-3503.

Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. 2010. Ki67

in breast cancer: prognostic and predictive potential. Lancet Oncol 11(2):174-
183.

Zierler BK. 2004. Ultrasonography and diagnosis of venous

thromboembolism. Circulation 109(12 Suppl 1):19-114.

Dosen: Prof Dr dr I Made Bakta SpPD-KHOM

 Tanda Tangan

SATUAN ACARA PERKULIAHAN (SAP) VII

1. MATA KULIAH CAT

2. KODE MATA KULIAH

3. WAKTU PERTEMUAN 50 Menit.

4. PERTEMUAN KE- 7.

5. INDIKATOR Mahasiswa mampu memahami tentang jenis-jenis

PENCAPAIAN antikoagulan
6. MATERI POKOK Jenis-jenis antikoagulan
7. PENGALAMAN BELAJAR Memahami tentang jenis-jenis antikoagulan
 STRATEGI PEMBELAJARAN

TAHAPAN KEGIATAN KEGIATAN MEDIA DAN ALAT

DOSEN MAHASISWA PEMBELAJARAN
(1) (2) (3) (4)
Pembukaan Memberikan ulasan Melihat, mendengarkan SAP, silabus dan jadwal
umum isi mata penjelasan study guide, text book,
kuliah tugas terstruktur, diktat,
slide presentasi

Penyajian Mengulas tentang Melihat, mendengarkan Idem

jenis-jenis penjelasan, serta mencatat
antikoagulan
Penutup Merangkum uraian Menyimak, mengajukan Idem
tentang jenis-jenis pertanyaan dan pendapat
antikoagulan dalam diskusi dan meyusun
laporan kegiatan selama
kuliah

Post test Ujian tertulis, lisan, penilaian/evaluasi terhadap proses pembelajaran, dan
unjuk sikap

Referensi
Afiati, Bethy S. Hernowo. 2013. Hubungan ekspresi Ki-67 dengan grading
histopatologi liposarkoma. Majalah kedokteran Bandung ; 45(3).

Agnelli G, Verso M, Ageno W. 2008. The MASTER registry on venous

thromboembolism: description of the study cohort. Thromb Res;121:605-610.

Aguilar C, delVillar V. 2007. Combined D-dimer and clinical probability are

useful for exclusion of recurrent deep venous thrombosis. Am J Hematol
82(1):41-4.

Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R,

Quehenberger P, Zielinski C, Pabinger I. 2010. Prediction of venous
thromboembolism in cancer patients. Blood 116(24):5377-82.

Birdwell BG, Raskob GE, Whitsett TL. 1998. The clinical validity of normal
compression ultrasonography in outpatients suspected of having deep venous
thrombosis. Ann Intern Med 128:1-7.

Brotman DJ, Segal JB, Jani JT, Petty BG, Kickler TS. 2003. Limitations of D-
dimer testing in unselected with suspected venous thromboembolism. Am J
Med 114(4):276282.

Bukhtoryarov OV, Samarin DM. 2015. Pathogenesis of cancer: cancer

reparative trap. Journal of Cancer Therapy 6:399-412.

Bystricky B, Reuben JM, Mego M. 2017. Circulating tumor cells and

coagulation: minirevew. J Crit Rev Onc 114:33-42.

Chew HK, Wun T, Harvey D. 2006. Incidence of venous thromboembolism

and its effect on survival among patients with common cancers. Arch Intern
Med 166:458-464.

Choi Y, Do Hoon Lim, Jeong Il Yu , Kyungil Jo , Do-Hyun Nam, Ho Jun Seol.

2015. Prognostic value of Ki-67 labeling index and postoperative
radiotherapy in WHO grade II Meningioma. Am J Clin Oncol 10:134-358.

Cohen AT, Tapson VF, Bergmann JF. 2008. Venous thromboembolism risk
and prophylaxis in the acute hospital care setting (ENDORSE study): a
multinational cross-sectional study. Lancet 371:387-394.

Collier MEW, Mah PM, Xiao Y, Maraveyas A, Ettelaie C. 2013.

Microparticle-associated tissue factor is recycled by endothelial cells resulting
in enhanched surface tissue factor activity. Thromb Journal 110:966-976.

Cui CJ, Wang GJ, Yang S, Huang SK, Qiao R, Cui W. 2018. Tissue factor
bearing MPs and the risk of venous thrombosis in cancer patients: a meta
analysis. Scientific Rep 8:1675

De Azambuja E, Cardoso F, de Castro G, Jr, Colozza M, Mano MS, Durbecq

V, Sotiriou C, Larsimont D, Piccart- Gebhart MJ, Paesmans M. 2007. Ki-67
as prognostic marker in early breast cancer: a meta-analysis of published
studies involving 12.155 patients. Br J Cancer 96:1504-1513.

Elyamany G, Alzahrani AM, Bukhary E. 2014. Cancer-associated thrombosis:

an overview. Clin Med Oncol 8:129-137

Ettelaie C, Mary EW Collier, Sophie Featherby, Naima E. Benelhaj, John

Greenman, and Anthony Maraveyas. 2016. Analysis of the potential of cancer
cell lines to release tissue factor-containing microvesicles: correlation with
tissue factor and PAR2 expression. Thromb Journal 14(2):1-12.

Falanga A, Russo L, Verzeroli C. 2013. Mechanism of thrombosis in cancer.

Thromb Res.;131:S59-62.

Fraser DG, Moody AR, Morgan PS, Martel A, Devidson I. 2002. Diagnosis of
lower-limb deep venous thrombosis: a prospective blinded study of magnetic
resonance direct thrombus imaging. Ann Intern Med 136(2):89-98.
Gaitini D. 2006. Current approaches and controversial issues in the diagnosis
of deep vein thrombosis via duplex Doppler ultrasound. J Clin Ultrasound
34:289-297.

Geddings JE, Mackman N. Tumor-derived tissue factor-positive

microparticles and venous thrombosis in cancer patients. Blood.
2013;122:1873-80.

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ.
2011. Strategies for subtypes dealing with the diversity of breast cancer:
highlights of the St. Gallen International Expert Consensus on the primary
therapy of early breast cancer Ann Oncol 22:1736-1747.

Heit JA, O'Fallon WM, Petterson TM. 2002. Relative impact of risk factors
for deep vein thrombosis and pulmonary embolism: a population-based study.
Arch Intern Med;162:1245-1248.

Hirsh J, Lee AY. 2002. How we diagnose and threat deep vein thrombosis.
Blood 99:3102-10.

Hisada Y, Gedding JE, Ay C, Mackman N. 2015. Venous thrombosis and

cancer: from mouse models to clinical trials. J Thromb Hem 13:1372-82.

Kakkar AK, Levine M, Pinedo HM. 2003. Venous thrombosis in cancer

patients: insights from the FRONTLINE survey. Oncologist 8:381-388.

Kearon C, Ginsberg JS, Douketis J. 2006. An evaluation of D-dimer in the

diagnosis of pulmonary embolism: a randomized trial. Ann Intern
Med;144:812-821.

Khorana AA, Dalal M, Lin J, Connolly GC. 2013. Incidence and predictors of
venous thromboembolism (VTE) among ambulatory high-risk cancer patients
undergoing chemotherapy in the United States. Cancer 119:648-655.

Khorana AA, Pieter W. Kamphuisen, Guy Meyer, Rupert Bauersachs, Mette

S, Janas, Mikala F.Jarner, Agness YY Lee. 2017. Tissue factor as a predictor
of recurrent venous thromboembolism in malignancy: biomarker analyses of
the catch trial. J Am Clin Onc 35(10):1128.

Levi M. 2016. Management of cancer associated disseminated intravascular

coagulation. Thrombo Res 140:66-70.

Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP,
Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine
MN, Liebman HA, Tempero MA, Wong SL, Prestrud AA, Falanga A. 2013.
Cancer and thrombosis: prevention and treatment of VTE in cancer patients. J
Clin Oncol 31(17):2189-2204.

Machowska M, Wachowicz K, Sopel M, Rzepecki R. 2014. Nuclear location

of tumor suppressor protein maspin inhibits proliferation of breast cancer cells
without affecting proliferation of normal epithelial cells. BMC Cancer 14:142-
148.

Martin B, Paesmans M, Mascaux C, Berghmans T, Lothaire P, Meert AP,

Lafitte JJ, Sculier JP. 2004. Ki-67 expression and patients survival in lung
cancer: systematic review of the literature with meta-analysis. Br J Cancer
91:2018-2025.

Navi BB, Anne S Reiner, Hooman Kamel, Costantino Iadecola, Peter M Okin,
Mitchell SV Elkind, Katherine S Panageas, Lisa M DeAngelis. 2017. Risk of
arterial thromboembolism in patient with cancer. J Am Coll Cardiol 70:926-
938.

Oudega R, Hoes AW, Moons KG. 2005. The Wells rule does not adequately
rule out deep venous thrombosis in primary care patients. Ann Intern Med
143(2):100-7.

Pabinger I. Biomarkers and venous thromboembolism. 2009. Arterioscler

Thromb Vasc Biol 29:332-6.

Prandoni P, Piccioli A, Girolami A. 1999. Cancer and venous

thromboembolism: an overview. Haematologica 84:437-445.

Rabinov K, Paulin S. 1992. Roentgen diagnosis of venous thrombosis in the

leg. Arch Surg.;104(2):134-44.

Razak NBA, Jones G, Bhandari M, Berndt MC, Metharom P. 2018. Cancer

associated thrombosis: an overview of mechanism, risk factors, and treatment.
Cancers 10 (380):1-10.

Sallah S, Wan JY, Nguyen NP. 2002. Venous thrombosis in patients with
solid tumors: determination of frequency and characteristics. Thromb Haemost
87:575-579.

Sampson FC, Goodacre SW, Thomas SM, van Beek EJ. 2007. The accuracy
of MRI in diagnosis of suspected deep vein thrombosis: systematic review and
meta-analysis. Eur Radiol 17:175-181.

Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. 2000. Prognosis of cancers
associated with venous thromboembolism. N Engl J Med 343:1846-1850.

Sorbye SW, Thomas K Kilvaer, Andrej Valkov, Tom Donnem, Eivind

Smeland, Khalid Al-Shibli, Roy M. Bremnes, Lill-Tove Busund. 2012.
Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue
sarcomas. PLoS One 7(10):e47068.

Tadbir AA, Pardis S, Ashkavandi ZJ, Najvani AD, Ashraf MJ, Taheri

A, Zadeh MASardari Y. 2012. Expression of Ki67 and CD105 as proliferation
and angiogenesis markers in salivary gland tumors. Asian Pac J Cancer Prev
13(10):5155-9.

Tao Li Lian, Guang Jiang,Qian Chen and Jun Nian Zheng. 2015. Ki67 is a
promising molecular target in the diagnosis of cancer. Review. Meleculer
Medicine Reports 11:1566-1572.

Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto
S. 2007. Microparticle-associated tissue factor activity: a link between cancer
and thrombosis? J Thromb Haemost 5(3):520-7.

Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. 2013. Epidemiology of
cancer-associated venous thrombosis. Blood 122:1712-1723.

Walker AJ, Baldwin DR, Card TR, Powel HA, Hubbard RB, Grainge MJ.
2016. Risk of venous thromboembolism in people with lung cancer: a cohort
study using linked UK healthcare data. B J Cancer 115:115-121.

Well PS, Anderson Dr, Bormanis J. 1997. Value of assessment of pretest

probability of deep vein thrombosis in clinical management. Lancet
350(9094):1795-1798.

Well PS, Anderson DR, Rodger M. 2003. Evaluation of D-dimer in the

diagnosis of suspected deep vein thrombosis. N Engl J Med 349:1227-1235.

Yang CF, Wu Cui, Jia-Lin Yao, Wen-Ying Sun, Xing-Ku Li, Hong-Jie Wu,
Zhao-Yang Hu, Xiao-Ming Zou. 2016. Plasma tissue factor levels and
microparticle-associated tissue factor activity in patients with gastric cancer.
Int J Clin Exp Pathol 9(3):3495-3503.

Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. 2010. Ki67

in breast cancer: prognostic and predictive potential. Lancet Oncol 11(2):174-
183.

Zierler BK. 2004. Ultrasonography and diagnosis of venous

 thromboembolism. Circulation 109(12 Suppl 1):19-114.

Dosen: Prof Dr dr I Made Bakta SpPD-KHOM

Tanda Tangan

SATUAN ACARA PERKULIAHAN (SAP) VIII

1. MATA KULIAH CAT

2. KODE MATA KULIAH

3. WAKTU PERTEMUAN 50 Menit.

4. PERTEMUAN KE- 8.

5. INDIKATOR Mahasiswa mampu memahami tentang profilaksis VTE

PENCAPAIAN
6. MATERI POKOK Profilaksis VTE
7. PENGALAMAN BELAJAR Memahami tentang profilaksis VTE

STRATEGI PEMBELAJARAN

TAHAPAN KEGIATAN KEGIATAN MEDIA DAN ALAT

DOSEN MAHASISWA PEMBELAJARAN
(1) (2) (3) (4)
Pembukaan Memberikan ulasan Melihat, mendengarkan SAP, silabus dan jadwal
umum isi mata penjelasan study guide, text book,
kuliah tugas terstruktur, diktat,
slide presentasi

Penyajian Mengulas tentang Melihat, mendengarkan Idem

profilaksis VTE penjelasan, serta mencatat
Penutup Merangkum uraian Menyimak, mengajukan Idem
tentang profilaksis pertanyaan dan pendapat
VTE dalam diskusi dan meyusun
laporan kegiatan selama
kuliah

Post test Ujian tertulis, lisan, penilaian/evaluasi terhadap proses pembelajaran, dan
unjuk sikap

Referensi
Afiati, Bethy S. Hernowo. 2013. Hubungan ekspresi Ki-67 dengan grading
histopatologi liposarkoma. Majalah kedokteran Bandung ; 45(3).

Agnelli G, Verso M, Ageno W. 2008. The MASTER registry on venous

thromboembolism: description of the study cohort. Thromb Res;121:605-610.

Aguilar C, delVillar V. 2007. Combined D-dimer and clinical probability are

useful for exclusion of recurrent deep venous thrombosis. Am J Hematol
82(1):41-4.

Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R,

Quehenberger P, Zielinski C, Pabinger I. 2010. Prediction of venous
thromboembolism in cancer patients. Blood 116(24):5377-82.

Birdwell BG, Raskob GE, Whitsett TL. 1998. The clinical validity of normal
compression ultrasonography in outpatients suspected of having deep venous
thrombosis. Ann Intern Med 128:1-7.

Brotman DJ, Segal JB, Jani JT, Petty BG, Kickler TS. 2003. Limitations of D-
dimer testing in unselected with suspected venous thromboembolism. Am J
Med 114(4):276282.

Bukhtoryarov OV, Samarin DM. 2015. Pathogenesis of cancer: cancer

reparative trap. Journal of Cancer Therapy 6:399-412.

Bystricky B, Reuben JM, Mego M. 2017. Circulating tumor cells and

coagulation: minirevew. J Crit Rev Onc 114:33-42.

Chew HK, Wun T, Harvey D. 2006. Incidence of venous thromboembolism

and its effect on survival among patients with common cancers. Arch Intern
Med 166:458-464.

Choi Y, Do Hoon Lim, Jeong Il Yu , Kyungil Jo , Do-Hyun Nam, Ho Jun Seol.

2015. Prognostic value of Ki-67 labeling index and postoperative
radiotherapy in WHO grade II Meningioma. Am J Clin Oncol 10:134-358.

Cohen AT, Tapson VF, Bergmann JF. 2008. Venous thromboembolism risk
and prophylaxis in the acute hospital care setting (ENDORSE study): a
multinational cross-sectional study. Lancet 371:387-394.

Collier MEW, Mah PM, Xiao Y, Maraveyas A, Ettelaie C. 2013.

Microparticle-associated tissue factor is recycled by endothelial cells resulting
in enhanched surface tissue factor activity. Thromb Journal 110:966-976.

Cui CJ, Wang GJ, Yang S, Huang SK, Qiao R, Cui W. 2018. Tissue factor
bearing MPs and the risk of venous thrombosis in cancer patients: a meta
analysis. Scientific Rep 8:1675

De Azambuja E, Cardoso F, de Castro G, Jr, Colozza M, Mano MS, Durbecq

V, Sotiriou C, Larsimont D, Piccart- Gebhart MJ, Paesmans M. 2007. Ki-67
as prognostic marker in early breast cancer: a meta-analysis of published
studies involving 12.155 patients. Br J Cancer 96:1504-1513.

Elyamany G, Alzahrani AM, Bukhary E. 2014. Cancer-associated thrombosis:

an overview. Clin Med Oncol 8:129-137

Ettelaie C, Mary EW Collier, Sophie Featherby, Naima E. Benelhaj, John

Greenman, and Anthony Maraveyas. 2016. Analysis of the potential of cancer
cell lines to release tissue factor-containing microvesicles: correlation with
tissue factor and PAR2 expression. Thromb Journal 14(2):1-12.

Falanga A, Russo L, Verzeroli C. 2013. Mechanism of thrombosis in cancer.

Thromb Res.;131:S59-62.

Fraser DG, Moody AR, Morgan PS, Martel A, Devidson I. 2002. Diagnosis of
lower-limb deep venous thrombosis: a prospective blinded study of magnetic
resonance direct thrombus imaging. Ann Intern Med 136(2):89-98.

Gaitini D. 2006. Current approaches and controversial issues in the diagnosis

of deep vein thrombosis via duplex Doppler ultrasound. J Clin Ultrasound
34:289-297.

Geddings JE, Mackman N. Tumor-derived tissue factor-positive

microparticles and venous thrombosis in cancer patients. Blood.
2013;122:1873-80.

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ.
2011. Strategies for subtypes dealing with the diversity of breast cancer:
highlights of the St. Gallen International Expert Consensus on the primary
therapy of early breast cancer Ann Oncol 22:1736-1747.

Heit JA, O'Fallon WM, Petterson TM. 2002. Relative impact of risk factors
for deep vein thrombosis and pulmonary embolism: a population-based study.
Arch Intern Med;162:1245-1248.

Hirsh J, Lee AY. 2002. How we diagnose and threat deep vein thrombosis.
Blood 99:3102-10.

Hisada Y, Gedding JE, Ay C, Mackman N. 2015. Venous thrombosis and

cancer: from mouse models to clinical trials. J Thromb Hem 13:1372-82.

Kakkar AK, Levine M, Pinedo HM. 2003. Venous thrombosis in cancer

patients: insights from the FRONTLINE survey. Oncologist 8:381-388.

Kearon C, Ginsberg JS, Douketis J. 2006. An evaluation of D-dimer in the

diagnosis of pulmonary embolism: a randomized trial. Ann Intern
Med;144:812-821.

Khorana AA, Dalal M, Lin J, Connolly GC. 2013. Incidence and predictors of
venous thromboembolism (VTE) among ambulatory high-risk cancer patients
undergoing chemotherapy in the United States. Cancer 119:648-655.

Khorana AA, Pieter W. Kamphuisen, Guy Meyer, Rupert Bauersachs, Mette

S, Janas, Mikala F.Jarner, Agness YY Lee. 2017. Tissue factor as a predictor
of recurrent venous thromboembolism in malignancy: biomarker analyses of
the catch trial. J Am Clin Onc 35(10):1128.

Levi M. 2016. Management of cancer associated disseminated intravascular

coagulation. Thrombo Res 140:66-70.
Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP,
Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine
MN, Liebman HA, Tempero MA, Wong SL, Prestrud AA, Falanga A. 2013.
Cancer and thrombosis: prevention and treatment of VTE in cancer patients. J
Clin Oncol 31(17):2189-2204.

Machowska M, Wachowicz K, Sopel M, Rzepecki R. 2014. Nuclear location

of tumor suppressor protein maspin inhibits proliferation of breast cancer cells
without affecting proliferation of normal epithelial cells. BMC Cancer 14:142-
148.

Martin B, Paesmans M, Mascaux C, Berghmans T, Lothaire P, Meert AP,

Lafitte JJ, Sculier JP. 2004. Ki-67 expression and patients survival in lung
cancer: systematic review of the literature with meta-analysis. Br J Cancer
91:2018-2025.

Navi BB, Anne S Reiner, Hooman Kamel, Costantino Iadecola, Peter M Okin,
Mitchell SV Elkind, Katherine S Panageas, Lisa M DeAngelis. 2017. Risk of
arterial thromboembolism in patient with cancer. J Am Coll Cardiol 70:926-
938.

Oudega R, Hoes AW, Moons KG. 2005. The Wells rule does not adequately
rule out deep venous thrombosis in primary care patients. Ann Intern Med
143(2):100-7.

Pabinger I. Biomarkers and venous thromboembolism. 2009. Arterioscler

Thromb Vasc Biol 29:332-6.

Prandoni P, Piccioli A, Girolami A. 1999. Cancer and venous

thromboembolism: an overview. Haematologica 84:437-445.

Rabinov K, Paulin S. 1992. Roentgen diagnosis of venous thrombosis in the

leg. Arch Surg.;104(2):134-44.

Razak NBA, Jones G, Bhandari M, Berndt MC, Metharom P. 2018. Cancer

associated thrombosis: an overview of mechanism, risk factors, and treatment.
Cancers 10 (380):1-10.

Sallah S, Wan JY, Nguyen NP. 2002. Venous thrombosis in patients with
solid tumors: determination of frequency and characteristics. Thromb Haemost
87:575-579.

Sampson FC, Goodacre SW, Thomas SM, van Beek EJ. 2007. The accuracy
of MRI in diagnosis of suspected deep vein thrombosis: systematic review and
meta-analysis. Eur Radiol 17:175-181.
Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. 2000. Prognosis of cancers
associated with venous thromboembolism. N Engl J Med 343:1846-1850.

Sorbye SW, Thomas K Kilvaer, Andrej Valkov, Tom Donnem, Eivind

Smeland, Khalid Al-Shibli, Roy M. Bremnes, Lill-Tove Busund. 2012.
Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue
sarcomas. PLoS One 7(10):e47068.

Tadbir AA, Pardis S, Ashkavandi ZJ, Najvani AD, Ashraf MJ, Taheri

A, Zadeh MASardari Y. 2012. Expression of Ki67 and CD105 as proliferation
and angiogenesis markers in salivary gland tumors. Asian Pac J Cancer Prev
13(10):5155-9.

Tao Li Lian, Guang Jiang,Qian Chen and Jun Nian Zheng. 2015. Ki67 is a
promising molecular target in the diagnosis of cancer. Review. Meleculer
Medicine Reports 11:1566-1572.

Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto
S. 2007. Microparticle-associated tissue factor activity: a link between cancer
and thrombosis? J Thromb Haemost 5(3):520-7.

Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. 2013. Epidemiology of
cancer-associated venous thrombosis. Blood 122:1712-1723.

Walker AJ, Baldwin DR, Card TR, Powel HA, Hubbard RB, Grainge MJ.
2016. Risk of venous thromboembolism in people with lung cancer: a cohort
study using linked UK healthcare data. B J Cancer 115:115-121.

Well PS, Anderson Dr, Bormanis J. 1997. Value of assessment of pretest

probability of deep vein thrombosis in clinical management. Lancet
350(9094):1795-1798.

Well PS, Anderson DR, Rodger M. 2003. Evaluation of D-dimer in the

diagnosis of suspected deep vein thrombosis. N Engl J Med 349:1227-1235.

Yang CF, Wu Cui, Jia-Lin Yao, Wen-Ying Sun, Xing-Ku Li, Hong-Jie Wu,
Zhao-Yang Hu, Xiao-Ming Zou. 2016. Plasma tissue factor levels and
microparticle-associated tissue factor activity in patients with gastric cancer.
Int J Clin Exp Pathol 9(3):3495-3503.

Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. 2010. Ki67

in breast cancer: prognostic and predictive potential. Lancet Oncol 11(2):174-
183.

Zierler BK. 2004. Ultrasonography and diagnosis of venous

 thromboembolism. Circulation 109(12 Suppl 1):19-114.

Dosen: Prof Dr dr I Made Bakta SpPD-KHOM

Tanda Tangan

SATUAN ACARA PERKULIAHAN (SAP) IX

1. MATA KULIAH CAT

2. KODE MATA KULIAH

3. WAKTU PERTEMUAN 50 Menit.

4. PERTEMUAN KE- 9.

5. INDIKATOR Mahasiswa mampu memahami tentang managemen VTE

PENCAPAIAN
6. MATERI POKOK Managemen VTE
7. PENGALAMAN BELAJAR Memahami tentang managemen VTE

STRATEGI PEMBELAJARAN

TAHAPAN KEGIATAN KEGIATAN MAHASISWA MEDIA DAN ALAT

DOSEN PEMBELAJARAN
(1) (2) (3) (4)
Pembukaan Memberikan Melihat, mendengarkan SAP, silabus dan jadwal
ulasan umum isi penjelasan study guide, text book,
mata kuliah tugas terstruktur, diktat,
slide presentasi

Penyajian Mengulas tentang Melihat, mendengarkan Idem

managemen VTE penjelasan, serta mencatat

Penutup Merangkum Menyimak, mengajukan Idem

uraian tentang pertanyaan dan pendapat
managemen VTE dalam diskusi dan meyusun
laporan kegiatan selama
kuliah
Post test Ujian tertulis, lisan, penilaian/evaluasi terhadap proses pembelajaran, dan
unjuk sikap

Referensi
Afiati, Bethy S. Hernowo. 2013. Hubungan ekspresi Ki-67 dengan grading
histopatologi liposarkoma. Majalah kedokteran Bandung ;45(3).

Agnelli G, Verso M, Ageno W. 2008. The MASTER registry on venous

thromboembolism: description of the study cohort. Thromb Res;121:605-610.

Aguilar C, delVillar V. 2007. Combined D-dimer and clinical probability are

useful for exclusion of recurrent deep venous thrombosis. Am J Hematol
82(1):41-4.

Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R,

Quehenberger P, Zielinski C, Pabinger I. 2010. Prediction of venous
thromboembolism in cancer patients. Blood 116(24):5377-82.

Birdwell BG, Raskob GE, Whitsett TL. 1998. The clinical validity of normal
compression ultrasonography in outpatients suspected of having deep venous
thrombosis. Ann Intern Med 128:1-7.

Brotman DJ, Segal JB, Jani JT, Petty BG, Kickler TS. 2003. Limitations of D-
dimer testing in unselected with suspected venous thromboembolism. Am J
Med 114(4):276282.

Bukhtoryarov OV, Samarin DM. 2015. Pathogenesis of cancer: cancer

reparative trap. Journal of Cancer Therapy 6:399-412.

Bystricky B, Reuben JM, Mego M. 2017. Circulating tumor cells and

coagulation: minirevew. J Crit Rev Onc 114:33-42.

Chew HK, Wun T, Harvey D. 2006. Incidence of venous thromboembolism

and its effect on survival among patients with common cancers. Arch Intern
Med 166:458-464.

Choi Y, Do Hoon Lim, Jeong Il Yu , Kyungil Jo , Do-Hyun Nam, Ho Jun Seol.

2015. Prognostic value of Ki-67 labeling index and postoperative
radiotherapy in WHO grade II Meningioma. Am J Clin Oncol 10:134-358.

Cohen AT, Tapson VF, Bergmann JF. 2008. Venous thromboembolism risk
and prophylaxis in the acute hospital care setting (ENDORSE study): a
multinational cross-sectional study. Lancet 371:387-394.

Collier MEW, Mah PM, Xiao Y, Maraveyas A, Ettelaie C. 2013.

Microparticle-associated tissue factor is recycled by endothelial cells resulting
in enhanched surface tissue factor activity. Thromb Journal 110:966-976.

Cui CJ, Wang GJ, Yang S, Huang SK, Qiao R, Cui W. 2018. Tissue factor
bearing MPs and the risk of venous thrombosis in cancer patients: a meta
analysis. Scientific Rep 8:1675

De Azambuja E, Cardoso F, de Castro G, Jr, Colozza M, Mano MS, Durbecq

V, Sotiriou C, Larsimont D, Piccart- Gebhart MJ, Paesmans M. 2007. Ki-67
as prognostic marker in early breast cancer: a meta-analysis of published
studies involving 12.155 patients. Br J Cancer 96:1504-1513.

Elyamany G, Alzahrani AM, Bukhary E. 2014. Cancer-associated thrombosis:

an overview. Clin Med Oncol 8:129-137

Ettelaie C, Mary EW Collier, Sophie Featherby, Naima E. Benelhaj, John

Greenman, and Anthony Maraveyas. 2016. Analysis of the potential of cancer
cell lines to release tissue factor-containing microvesicles: correlation with
tissue factor and PAR2 expression. Thromb Journal 14(2):1-12.

Falanga A, Russo L, Verzeroli C. 2013. Mechanism of thrombosis in cancer.

Thromb Res.;131:S59-62.

Fraser DG, Moody AR, Morgan PS, Martel A, Devidson I. 2002. Diagnosis of
lower-limb deep venous thrombosis: a prospective blinded study of magnetic
resonance direct thrombus imaging. Ann Intern Med 136(2):89-98.

Gaitini D. 2006. Current approaches and controversial issues in the diagnosis

of deep vein thrombosis via duplex Doppler ultrasound. J Clin Ultrasound
34:289-297.

Geddings JE, Mackman N. Tumor-derived tissue factor-positive

microparticles and venous thrombosis in cancer patients. Blood.
2013;122:1873-80.

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ.
2011. Strategies for subtypes dealing with the diversity of breast cancer:
highlights of the St. Gallen International Expert Consensus on the primary
therapy of early breast cancer Ann Oncol 22:1736-1747.

Heit JA, O'Fallon WM, Petterson TM. 2002. Relative impact of risk factors
for deep vein thrombosis and pulmonary embolism: a population-based study.
Arch Intern Med;162:1245-1248.

Hirsh J, Lee AY. 2002. How we diagnose and threat deep vein thrombosis.
Blood 99:3102-10.

Hisada Y, Gedding JE, Ay C, Mackman N. 2015. Venous thrombosis and

cancer: from mouse models to clinical trials. J Thromb Hem 13:1372-82.

Kakkar AK, Levine M, Pinedo HM. 2003. Venous thrombosis in cancer

patients: insights from the FRONTLINE survey. Oncologist 8:381-388.

Kearon C, Ginsberg JS, Douketis J. 2006. An evaluation of D-dimer in the

diagnosis of pulmonary embolism: a randomized trial. Ann Intern
Med;144:812-821.

Khorana AA, Dalal M, Lin J, Connolly GC. 2013. Incidence and predictors of
venous thromboembolism (VTE) among ambulatory high-risk cancer patients
undergoing chemotherapy in the United States. Cancer 119:648-655.

Khorana AA, Pieter W. Kamphuisen, Guy Meyer, Rupert Bauersachs, Mette

S, Janas, Mikala F.Jarner, Agness YY Lee. 2017. Tissue factor as a predictor
of recurrent venous thromboembolism in malignancy: biomarker analyses of
the catch trial. J Am Clin Onc 35(10):1128.

Levi M. 2016. Management of cancer associated disseminated intravascular

coagulation. Thrombo Res 140:66-70.

Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP,
Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine
MN, Liebman HA, Tempero MA, Wong SL, Prestrud AA, Falanga A. 2013.
Cancer and thrombosis: prevention and treatment of VTE in cancer patients. J
Clin Oncol 31(17):2189-2204.

Machowska M, Wachowicz K, Sopel M, Rzepecki R. 2014. Nuclear location

of tumor suppressor protein maspin inhibits proliferation of breast cancer cells
without affecting proliferation of normal epithelial cells. BMC Cancer 14:142-
148.

Martin B, Paesmans M, Mascaux C, Berghmans T, Lothaire P, Meert AP,

Lafitte JJ, Sculier JP. 2004. Ki-67 expression and patients survival in lung
cancer: systematic review of the literature with meta-analysis. Br J Cancer
91:2018-2025.

Navi BB, Anne S Reiner, Hooman Kamel, Costantino Iadecola, Peter M Okin,
Mitchell SV Elkind, Katherine S Panageas, Lisa M DeAngelis. 2017. Risk of
arterial thromboembolism in patient with cancer. J Am Coll Cardiol 70:926-
938.

Oudega R, Hoes AW, Moons KG. 2005. The Wells rule does not adequately
rule out deep venous thrombosis in primary care patients. Ann Intern Med
143(2):100-7.

Pabinger I. Biomarkers and venous thromboembolism. 2009. Arterioscler

Thromb Vasc Biol 29:332-6.

Prandoni P, Piccioli A, Girolami A. 1999. Cancer and venous

thromboembolism: an overview. Haematologica 84:437-445.

Rabinov K, Paulin S. 1992. Roentgen diagnosis of venous thrombosis in the

leg. Arch Surg.;104(2):134-44.

Razak NBA, Jones G, Bhandari M, Berndt MC, Metharom P. 2018. Cancer

associated thrombosis: an overview of mechanism, risk factors, and treatment.
Cancers 10 (380):1-10.

Sallah S, Wan JY, Nguyen NP. 2002. Venous thrombosis in patients with
solid tumors: determination of frequency and characteristics. Thromb Haemost
87:575-579.

Sampson FC, Goodacre SW, Thomas SM, van Beek EJ. 2007. The accuracy
of MRI in diagnosis of suspected deep vein thrombosis: systematic review and
meta-analysis. Eur Radiol 17:175-181.

Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. 2000. Prognosis of cancers
associated with venous thromboembolism. N Engl J Med 343:1846-1850.

Sorbye SW, Thomas K Kilvaer, Andrej Valkov, Tom Donnem, Eivind

Smeland, Khalid Al-Shibli, Roy M. Bremnes, Lill-Tove Busund. 2012.
Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue
sarcomas. PLoS One 7(10):e47068.

Tadbir AA, Pardis S, Ashkavandi ZJ, Najvani AD, Ashraf MJ, Taheri

A, Zadeh MASardari Y. 2012. Expression of Ki67 and CD105 as proliferation
and angiogenesis markers in salivary gland tumors. Asian Pac J Cancer Prev
13(10):5155-9.

Tao Li Lian, Guang Jiang,Qian Chen and Jun Nian Zheng. 2015. Ki67 is a
promising molecular target in the diagnosis of cancer. Review. Meleculer
Medicine Reports 11:1566-1572.

Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto
S. 2007. Microparticle-associated tissue factor activity: a link between cancer
and thrombosis? J Thromb Haemost 5(3):520-7.

Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. 2013. Epidemiology of
cancer-associated venous thrombosis. Blood 122:1712-1723.

Walker AJ, Baldwin DR, Card TR, Powel HA, Hubbard RB, Grainge MJ.
2016. Risk of venous thromboembolism in people with lung cancer: a cohort
study using linked UK healthcare data. B J Cancer 115:115-121.

Well PS, Anderson Dr, Bormanis J. 1997. Value of assessment of pretest

probability of deep vein thrombosis in clinical management. Lancet
350(9094):1795-1798.

Well PS, Anderson DR, Rodger M. 2003. Evaluation of D-dimer in the

diagnosis of suspected deep vein thrombosis. N Engl J Med 349:1227-1235.

Yang CF, Wu Cui, Jia-Lin Yao, Wen-Ying Sun, Xing-Ku Li, Hong-Jie Wu,
Zhao-Yang Hu, Xiao-Ming Zou. 2016. Plasma tissue factor levels and
microparticle-associated tissue factor activity in patients with gastric cancer.
 Int J Clin Exp Pathol 9(3):3495-3503.

Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. 2010. Ki67

in breast cancer: prognostic and predictive potential. Lancet Oncol 11(2):174-
183.

Zierler BK. 2004. Ultrasonography and diagnosis of venous

thromboembolism. Circulation 109(12 Suppl 1):19-114.

Dosen: Prof Dr dr I Made Bakta SpPD-KHOM

Tanda Tangan

SATUAN ACARA PERKULIAHAN (SAP) X

1. MATA KULIAH CAT

2. KODE MATA KULIAH

3. WAKTU PERTEMUAN 50 Menit.

4. PERTEMUAN KE- 10.

5. INDIKATOR Mahasiswa mampu memahami penilaian respon terapi

PENCAPAIAN VTE

6. MATERI POKOK Respon terapi VTE

7. PENGALAMAN BELAJAR Memahami penilaian respon terapi VTE

STRATEGI PEMBELAJARAN

TAHAPAN KEGIATAN DOSEN KEGIATAN MEDIA DAN ALAT

MAHASISWA PEMBELAJARAN
(1) (2) (3) (4)
Pembukaan Memberikan ulasan Melihat, mendengarkan SAP, silabus dan jadwal
umum isi mata kuliah penjelasan study guide, text book,
tugas terstruktur, diktat,
slide presentasi

Penyajian Mengulas tentang Melihat, mendengarkan Idem

penilaian respon terapi penjelasan, serta
VTE mencatat

Penutup Merangkum uraian Menyimak, mengajukan Idem

tentang penilaian pertanyaan dan
respon terapi VTE pendapat dalam diskusi
dan meyusun laporan
kegiatan selama kuliah

Post test Ujian tertulis, lisan, penilaian/evaluasi terhadap proses pembelajaran, dan
unjuk sikap

Referensi Afiati, Bethy S. Hernowo. 2013. Hubungan ekspresi Ki-67 dengan grading
histopatologi liposarkoma. Majalah kedokteran Bandung ; 45(3).

Agnelli G, Verso M, Ageno W. 2008. The MASTER registry on venous

thromboembolism: description of the study cohort. Thromb Res;121:605-610.

Aguilar C, delVillar V. 2007. Combined D-dimer and clinical probability are

useful for exclusion of recurrent deep venous thrombosis. Am J Hematol
82(1):41-4.

Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R,

Quehenberger P, Zielinski C, Pabinger I. 2010. Prediction of venous
thromboembolism in cancer patients. Blood 116(24):5377-82.

Birdwell BG, Raskob GE, Whitsett TL. 1998. The clinical validity of normal
compression ultrasonography in outpatients suspected of having deep venous
thrombosis. Ann Intern Med 128:1-7.

Brotman DJ, Segal JB, Jani JT, Petty BG, Kickler TS. 2003. Limitations of D-
dimer testing in unselected with suspected venous thromboembolism. Am J
Med 114(4):276282.

Bukhtoryarov OV, Samarin DM. 2015. Pathogenesis of cancer: cancer

reparative trap. Journal of Cancer Therapy 6:399-412.

Bystricky B, Reuben JM, Mego M. 2017. Circulating tumor cells and

coagulation: minirevew. J Crit Rev Onc 114:33-42.

Chew HK, Wun T, Harvey D. 2006. Incidence of venous thromboembolism

and its effect on survival among patients with common cancers. Arch Intern
Med 166:458-464.

Choi Y, Do Hoon Lim, Jeong Il Yu , Kyungil Jo , Do-Hyun Nam, Ho Jun Seol.

2015. Prognostic value of Ki-67 labeling index and postoperative
radiotherapy in WHO grade II Meningioma. Am J Clin Oncol 10:134-358.

Cohen AT, Tapson VF, Bergmann JF. 2008. Venous thromboembolism risk
and prophylaxis in the acute hospital care setting (ENDORSE study): a
multinational cross-sectional study. Lancet 371:387-394.

Collier MEW, Mah PM, Xiao Y, Maraveyas A, Ettelaie C. 2013.

Microparticle-associated tissue factor is recycled by endothelial cells resulting
in enhanched surface tissue factor activity. Thromb Journal 110:966-976.

Cui CJ, Wang GJ, Yang S, Huang SK, Qiao R, Cui W. 2018. Tissue factor
bearing MPs and the risk of venous thrombosis in cancer patients: a meta
analysis. Scientific Rep 8:1675

De Azambuja E, Cardoso F, de Castro G, Jr, Colozza M, Mano MS, Durbecq

V, Sotiriou C, Larsimont D, Piccart- Gebhart MJ, Paesmans M. 2007. Ki-67
as prognostic marker in early breast cancer: a meta-analysis of published
studies involving 12.155 patients. Br J Cancer 96:1504-1513.
Elyamany G, Alzahrani AM, Bukhary E. 2014. Cancer-associated thrombosis:
an overview. Clin Med Oncol 8:129-137

Ettelaie C, Mary EW Collier, Sophie Featherby, Naima E. Benelhaj, John

Greenman, and Anthony Maraveyas. 2016. Analysis of the potential of cancer
cell lines to release tissue factor-containing microvesicles: correlation with
tissue factor and PAR2 expression. Thromb Journal 14(2):1-12.

Falanga A, Russo L, Verzeroli C. 2013. Mechanism of thrombosis in cancer.

Thromb Res.;131:S59-62.

Fraser DG, Moody AR, Morgan PS, Martel A, Devidson I. 2002. Diagnosis of
lower-limb deep venous thrombosis: a prospective blinded study of magnetic
resonance direct thrombus imaging. Ann Intern Med 136(2):89-98.

Gaitini D. 2006. Current approaches and controversial issues in the diagnosis

of deep vein thrombosis via duplex Doppler ultrasound. J Clin Ultrasound
34:289-297.

Geddings JE, Mackman N. Tumor-derived tissue factor-positive

microparticles and venous thrombosis in cancer patients. Blood.
2013;122:1873-80.

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ.
2011. Strategies for subtypes dealing with the diversity of breast cancer:
highlights of the St. Gallen International Expert Consensus on the primary
therapy of early breast cancer Ann Oncol 22:1736-1747.

Heit JA, O'Fallon WM, Petterson TM. 2002. Relative impact of risk factors
for deep vein thrombosis and pulmonary embolism: a population-based study.
Arch Intern Med;162:1245-1248.

Hirsh J, Lee AY. 2002. How we diagnose and threat deep vein thrombosis.
Blood 99:3102-10.

Hisada Y, Gedding JE, Ay C, Mackman N. 2015. Venous thrombosis and

cancer: from mouse models to clinical trials. J Thromb Hem 13:1372-82.

Kakkar AK, Levine M, Pinedo HM. 2003. Venous thrombosis in cancer

patients: insights from the FRONTLINE survey. Oncologist 8:381-388.

Kearon C, Ginsberg JS, Douketis J. 2006. An evaluation of D-dimer in the

diagnosis of pulmonary embolism: a randomized trial. Ann Intern
Med;144:812-821.
Khorana AA, Dalal M, Lin J, Connolly GC. 2013. Incidence and predictors of
venous thromboembolism (VTE) among ambulatory high-risk cancer patients
undergoing chemotherapy in the United States. Cancer 119:648-655.

Khorana AA, Pieter W. Kamphuisen, Guy Meyer, Rupert Bauersachs, Mette

S, Janas, Mikala F.Jarner, Agness YY Lee. 2017. Tissue factor as a predictor
of recurrent venous thromboembolism in malignancy: biomarker analyses of
the catch trial. J Am Clin Onc 35(10):1128.

Levi M. 2016. Management of cancer associated disseminated intravascular

coagulation. Thrombo Res 140:66-70.

Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP,
Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine
MN, Liebman HA, Tempero MA, Wong SL, Prestrud AA, Falanga A. 2013.
Cancer and thrombosis: prevention and treatment of VTE in cancer patients. J
Clin Oncol 31(17):2189-2204.

Machowska M, Wachowicz K, Sopel M, Rzepecki R. 2014. Nuclear location

of tumor suppressor protein maspin inhibits proliferation of breast cancer cells
without affecting proliferation of normal epithelial cells. BMC Cancer 14:142-
148.

Martin B, Paesmans M, Mascaux C, Berghmans T, Lothaire P, Meert AP,

Lafitte JJ, Sculier JP. 2004. Ki-67 expression and patients survival in lung
cancer: systematic review of the literature with meta-analysis. Br J Cancer
91:2018-2025.

Navi BB, Anne S Reiner, Hooman Kamel, Costantino Iadecola, Peter M Okin,
Mitchell SV Elkind, Katherine S Panageas, Lisa M DeAngelis. 2017. Risk of
arterial thromboembolism in patient with cancer. J Am Coll Cardiol 70:926-
938.

Oudega R, Hoes AW, Moons KG. 2005. The Wells rule does not adequately
rule out deep venous thrombosis in primary care patients. Ann Intern Med
143(2):100-7.

Pabinger I. Biomarkers and venous thromboembolism. 2009. Arterioscler

Thromb Vasc Biol 29:332-6.

Prandoni P, Piccioli A, Girolami A. 1999. Cancer and venous

thromboembolism: an overview. Haematologica 84:437-445.

Rabinov K, Paulin S. 1992. Roentgen diagnosis of venous thrombosis in the

leg. Arch Surg.;104(2):134-44.
Razak NBA, Jones G, Bhandari M, Berndt MC, Metharom P. 2018. Cancer
associated thrombosis: an overview of mechanism, risk factors, and treatment.
Cancers 10 (380):1-10.

Sallah S, Wan JY, Nguyen NP. 2002. Venous thrombosis in patients with
solid tumors: determination of frequency and characteristics. Thromb Haemost
87:575-579.

Sampson FC, Goodacre SW, Thomas SM, van Beek EJ. 2007. The accuracy
of MRI in diagnosis of suspected deep vein thrombosis: systematic review and
meta-analysis. Eur Radiol 17:175-181.

Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. 2000. Prognosis of cancers
associated with venous thromboembolism. N Engl J Med 343:1846-1850.

Sorbye SW, Thomas K Kilvaer, Andrej Valkov, Tom Donnem, Eivind

Smeland, Khalid Al-Shibli, Roy M. Bremnes, Lill-Tove Busund. 2012.
Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue
sarcomas. PLoS One 7(10):e47068.

Tadbir AA, Pardis S, Ashkavandi ZJ, Najvani AD, Ashraf MJ, Taheri

A, Zadeh MASardari Y. 2012. Expression of Ki67 and CD105 as proliferation
and angiogenesis markers in salivary gland tumors. Asian Pac J Cancer Prev
13(10):5155-9.

Tao Li Lian, Guang Jiang,Qian Chen and Jun Nian Zheng. 2015. Ki67 is a
promising molecular target in the diagnosis of cancer. Review. Meleculer
Medicine Reports 11:1566-1572.

Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto
S. 2007. Microparticle-associated tissue factor activity: a link between cancer
and thrombosis? J Thromb Haemost 5(3):520-7.

Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. 2013. Epidemiology of
cancer-associated venous thrombosis. Blood 122:1712-1723.

Walker AJ, Baldwin DR, Card TR, Powel HA, Hubbard RB, Grainge MJ.
2016. Risk of venous thromboembolism in people with lung cancer: a cohort
study using linked UK healthcare data. B J Cancer 115:115-121.

Well PS, Anderson Dr, Bormanis J. 1997. Value of assessment of pretest

probability of deep vein thrombosis in clinical management. Lancet
350(9094):1795-1798.

Well PS, Anderson DR, Rodger M. 2003. Evaluation of D-dimer in the

diagnosis of suspected deep vein thrombosis. N Engl J Med 349:1227-1235.

Yang CF, Wu Cui, Jia-Lin Yao, Wen-Ying Sun, Xing-Ku Li, Hong-Jie Wu,
Zhao-Yang Hu, Xiao-Ming Zou. 2016. Plasma tissue factor levels and
microparticle-associated tissue factor activity in patients with gastric cancer.
Int J Clin Exp Pathol 9(3):3495-3503.

Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. 2010. Ki67

in breast cancer: prognostic and predictive potential. Lancet Oncol 11(2):174-
183.

Zierler BK. 2004. Ultrasonography and diagnosis of venous

thromboembolism. Circulation 109(12 Suppl 1):19-114.

Dosen: Prof Dr dr I Made Bakta SpPD-KHOM

Tanda Tangan